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1.1. Summary (English version) 
As in other industrialised countries, the HIV epidemic in Spain is not generalised 
but concentrates predominantly in vulnerable groups. Some of the factors that in-
crease vulnerability are migrant and ethnic minority status, poor economic situation, 
and low socioeconomic level. Moreover, there is a risk that the most vulnerable popu-
lations may be the very ones who are also least likely to benefit from available treat-
ment resources, contributing doubly to increased health inequalities.  
Delayed diagnosis, worse access to treatment, limited effectiveness of available 
therapies and worse disease progression (i.e., higher incidence of AIDS and higher 
mortality) are ways in which inequalities may be expressed. The objective of this Doc-
toral Thesis is to study the effect of educational level and migration status over key 
HIV-related outcomes, in order to assess the impact of social inequalities over the 
course of HIV disease. 
Data from three open, multicentre, prospective cohorts of patients over 13 
years of age with confirmed HIV infection have been analysed. Two of them are sero-
converter cohorts: the Madrid Seroconverter cohort recruited in the Centro Sanitario 
Sandoval, and the GEMES cohort. The third one, the CoRIS cohort, is a seroprevalent 
cohort of subjects naïve to antiretroviral treatment at entry. 
 A survival analysis was carried out. Kaplan-Meier function and Cox proportional 
hazards model were used to study overall survival and to evaluate its associated fac-
tors. For other outcomes, a competing risk methodology was used, including multiple 
decrements method and Fine & Gray regression. Censoring strategies varied between 
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cohorts and between different outcomes, and sensitivity analyses under different as-
sumptions were performed. 
Availability of HAART after 1996 showed great population effectiveness in re-
ducing AIDS incidence and mortality in HIV infected patients in the Spanish context. 
However, people of low educational level benefit to a lesser extent, which reflects in a 
higher risk of progression to AIDS that becomes evident after HAART became available; 
and the inequality gap is further widened as treatments become more effective. 
Higher all-cause mortality is also evident, but is not affected by the availability of 
HAART. However, no difference is found on access to HAART by educational level. 
Compared to native Spanish, migrants from Latin America and Sub-Saharan Af-
rica experience a higher risk of delayed diagnosis of HIV infection, specially the 
younger subjects, probably reflecting the existence of barriers to HIV testing. However 
no meaningful delays in treatment initiation are identified, showing no further barriers 
for migrants once they have accessed the system. Migrants from Latin America and 
Sub-Saharan Africa aged between 35 to 50 years progress faster to an AIDS diagnosis, 
at the expense of a higher incidence rate of tuberculosis. In contrast, mortality in these 
groups tends to be lower, compatible with the healthy migrant effect. Immunological 
and virological response to antiretroviral treatment is poorer for Sub-Saharan Africans, 
but not for Latin Americans. 
These results are important to inform appropriate preventive and health care 
services as well as health programmes and policies to better respond to challenges 
posed by social inequalities and to reduce their impact on health. 
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1.2. Resumen (versión en Español) 
Al igual que en otros países industrializados, la epidemia del VIH en España no 
está generalizada, sino predominantemente concentrada en grupos vulnerables. Fac-
tores que aumentan la vulnerabilidad son el estatus de migrante y minorías étnicas, la 
mala situación económica y el bajo nivel socioeconómico. Además, existe el riesgo de 
que precisamente las poblaciones más vulnerables se beneficien menos de los recur-
sos disponibles, contribuyendo doblemente a aumentar las desigualdades en salud.  
Estas desigualdades pueden manifestarse como mayor retraso diagnóstico, ba-
rreras para el acceso al tratamiento, efectividad limitada del mismo y peor progresión 
de la infección, es decir, una mayor incidencia de SIDA y de mortalidad. El objetivo de 
esta Tesis Doctoral es estudiar el efecto del nivel educativo y el estatus migratorio so-
bre resultados clave relacionados con el VIH, con el fin de evaluar el impacto de las 
desigualdades sociales sobre el curso de la infección por VIH. 
 Se han analizado datos de tres cohortes abiertas, multicéntricas y prospectivas 
de sujetos mayores de 13 años con infección VIH confirmada. Dos de ellas son cohor-
tes de seroconvertores: la cohorte de seroconvertores de Madrid, reclutada en el Cen-
tro Sanitario Sandoval, y la cohorte GEMES. La tercera, la cohorte CoRIS, es una cohor-
te de sujetos seroprevalentes naïve a tratamiento antirretroviral al reclutamiento. 
Se realizó un análisis de supervivencia. Para la supervivencia global y los facto-
res asociados se usaron la función de Kaplan-Meier y el modelo de riesgos proporcio-
nales de Cox. Para otros eventos, se usaron métodos de riesgos competitivos, inclu-
yendo el método de decrementos múltiples y la regresión de Fine&Gray. La estrategia 
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de censura varió en función de la cohorte y del evento y se realizaron análisis de sensi-
bilidad con distintas asunciones. 
La disponibilidad de TARGA después de 1996 ha mostrado gran efectividad po-
blacional en la reducción de la incidencia de SIDA y la mortalidad de las personas infec-
tadas por el VIH en el contexto español. Sin embargo, las personas con bajo nivel edu-
cativo se benefician en menor medida, lo que se refleja en mayor riesgo de progresión 
a SIDA tras la disponibilidad de TARGA; y la brecha de desigualdad aumenta conforme 
los tratamientos son más eficaces. También se evidencia una mayor mortalidad global, 
que no se ve afectada por la disponibilidad de TARGA. Sin embargo, no se encuentran 
diferencias en el acceso al tratamiento en función del nivel educativo. 
En comparación con los españoles, los migrantes de América Latina y África 
Subsahariana presentan mayor riesgo de retraso diagnóstico, especialmente los más 
jóvenes, reflejando probablemente la existencia de barreras a la prueba del VIH. Sin 
embargo, no se han detectado retrasos significativos en el inicio del tratamiento, mos-
trando la ausencia de barreras adicionales una vez han accedido al sistema. Los mi-
grantes de ambos orígenes entre 35 y 50 años progresan más rápidamente a SIDA, 
debido a la tuberculosis. Al contrario, la mortalidad tiende a ser menor, compatible 
con el efecto del inmigrante sano. La respuesta inmunológica y virológica al tratamien-
to es peor en las personas de África Subsahariana, pero no en los Latinoamericanos.  
Estos resultados son importantes para orientar los servicios preventivos y asis-
tenciales, así como los programas y políticas de salud, para responder mejor a los retos 
planteados por las desigualdades sociales y para ser capaces de reducir su impacto en 
salud. 
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2.1. Epidemiology of HIV infection  
2.1.1. A look at the global HIV epidemic 
After 30 years of ongoing HIV/AIDS epidemic and according to 2010 UNAIDS 
data [1, 2], the overall growth of the global AIDS epidemic appears to have stabilized in 
an estimated prevalence of 0.8%. The annual number of new HIV infections has fallen 
by 19% since 1999, the year in which it is thought that the epidemic peaked, and there 
are fewer AIDS-related deaths due to the significant scaling up of antiretroviral therapy 
over the past few years. However, access to treatment still needs to be expanded: of 
the estimated 15 million people living with HIV in low- and middle-income countries 
who need treatment, only 5.2 million have access to it.  
Despite the optimistic global figures, HIV/AIDS pandemic reflects the socio-
economic and health inequalities between industrialised and non-industrialised coun-
tries very clearly. In 2009, 68% of the 33.3 million people infected with HIV worldwide 
lived in Sub-Saharan Africa, and over 97% of new HIV infections took place in low- and 
middle-income countries.  
Sub-Saharan Africa (SSA) is the area most severely hit by the HIV/AIDS pan-
demic, where prevalence rates in adult population aged 15–49 were estimated to be 
5% in 2009. Of the 1.8 million people who died of AIDS that year, 1.3 million lived in 
SSA where universal access to HAART is still far from being achieved. The epidemic in 
SSA is largely a heterosexual epidemic, with an increasing number of women being 
infected, and a significant number of vertically infected children.  
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The Caribbean, with an adult HIV prevalence of 1%, is the second most affected 
region. There is, nevertheless, substantial heterogeneity within the islands, the Do-
minican Republic being the most affected one. HIV in the Caribbean is predominantly 
transmitted through heterosexual intercourse and shows characteristics of a general-
ised epidemic, very much like Sub-Saharan Africa’s. Moreover, the Caribbean is the 
only region outside SSA where HIV infected women outnumber men. 
Eastern Europe and Central Asia rank third in worldwide HIV prevalence (of 
0.8%), with an incidence rate in Eastern Europe over twice the rate of Western Europe. 
90% of HIV-infected people in this region live in Russia or Ukraine. This region has ex-
perienced one of the most recent and explosive epidemics, largely driven by injecting 
drug use (IDU). The number of AIDS cases in this region also continues to increase[3].  
In Latin America, HIV prevalence is around 0.5%, again with some differences 
between countries, being higher in countries surrounding the Caribbean. Transmission 
in the region is mainly through sex between men, although a meaningful transmission 
through injecting drug use was observed in the Southern Cone, mainly at the beginning 
of the AIDS epidemic. Consequently, the HIV/AIDS epidemic in this region is highly 
masculinised. 
Among high-income regions, North America reported an adult prevalence of 
0.5%, more than double than Western and Central Europe with a 0.2%. Epidemics 
within industrialised countries are transmitted mainly through sex between men, are 
highly masculinised and show a concentrated pattern. Large inequalities have been 
reported within countries: in 2008 the United States found HIV prevalence in Afro-
Americans (1.8%) and Hispanics (0.6%) to be significantly higher than in Caucasians 
Socioeconomic factors and HIV-related outcomes: Delayed diagnosis, access to treatment and disease progression 
11 
(0.2%)[4]. In Europe, migrant populations, largely from Sub-Saharan Africa, repre-
sented a considerable and growing proportion of both the AIDS cases and HIV infec-
tions reported in the 27 EU countries plus Norway and Iceland during 1999–2006[5, 6]. 
2.1.2. The HIV epidemic in Spain: the 80’s and the 90’s  
During the last two decades of the 20th Century, Spain suffered one of the larg-
est HIV epidemics in Europe. Against a background of an injected heroin consumption 
boom that took place in the country in the late ’70 and beginning of the ‘80, HIV ex-
panded rapidly among drug users, new infections peaking between 1984 and 1987. 
The epidemic in men who have sex with men (MSM) was less pronounced, in contrast 
with the situation in other industrialized countries, where homosexual intercourse was 
the predominant route of transmission. Injecting drug users (IDU) were mainly young, 
sexually active individuals, so heterosexual transmission started to rise, together with 
cases of mother to child transmission. The implementation of harm reduction pro-
grammes for drug users, the abandonment of injection as the preferred route for drug 
uptake and other prevention measures managed to change the course of the epidemic 
in Spain, and transmission started to decrease in the late 80’s[7].  
AIDS cases rose accordingly until the mid 90’s, when AIDS came to be the first 
cause of death in subjects from 25-44 years old[8], with incidence rates higher than 
anywhere else in Europe. The generalisation of HAART in 1997 completely changed the 
course of the HIV infection, drastically reducing the incidence of AIDS and the AIDS 
related mortality [9-11].  
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2.1.3. Current HIV epidemic figures and challenges 
HIV epidemic profile in Spain has changed very much in the last decade, level-
ling with the epidemics of its neighbouring countries. New diagnoses have been con-
tinuously decreasing to reach 88.5 cases per million in 2010 and, from 1996 to 2010, 
an 83% reduction in AIDS cases has been observed. Due to the decrease in the number 
of new infections and the drop in mortality, the number of persons living with HIV in 
Spain has stabilised in 120,000 – 150,000 subjects, for an estimated prevalence of 3 
per 1,000.  
As for the current epidemic profile, the national information system on new 
HIV diagnosis (SINIVIH) has been widening its population coverage and it currently 
represents 71% of the Spanish population. According to SINIVIH data, a shift has been 
observed towards a predominantly sexually transmitted epidemic[12]. Sex between 
men is the main route of infection (46% of new diagnoses in 2010), and this is the only 
group where the rate of new diagnoses has been increasing in the last decade. This 
determines a highly masculinised epidemic, with an 80% of males. In contrast, nowa-
days IDU stand for as low as 6% of HIV diagnoses. The proportion of people originating 
from countries outside Spain has increased during the last decade to reach 38.4% of 
HIV diagnoses[12]. The fact that the majority of migrants originate from countries 
where the predominant routes of infection are sexual has also contributed to the sex-
ualisation of the Spanish epidemic. 
In recent years, however, the decline in AIDS cases has been less steep, proba-
bly because we are close to reaching the maximum benefits of HAART availability, but 
also because efficacy of treatment is dependent on starting treatment on time. Late 
Socioeconomic factors and HIV-related outcomes: Delayed diagnosis, access to treatment and disease progression 
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presentation of patients for care may limit effectiveness and makes early diagnosis of 
infection a cornerstone of HIV management. In 2010 in Spain, 45.4% of patients were 
diagnosed with less than 350 CD4 cells/μL[12], which is considered a late diagnosis[13] 
and involves a worse prognosis at the individual level.  
But late diagnosis is also key from the public health perspective, as it has been 
estimated that undiagnosed HIV-positive subjects have a transmission rate 3.5 times 
higher than those who are aware of their HIV-infection[14]. In Spain, an approximate 
30% of HIV infected persons are unaware of their sero-status[7]. All this makes diagno-
sis of HIV infection one of the main challenges for the HIV epidemic control nowadays. 
Finally, as in other industrialised countries, HIV epidemic in Spain is not general-
ised, but concentrates predominantly in vulnerable groups. Some of the factors that 
increase vulnerability are migrant and ethnic minority status, poor economic situation, 
and low socioeconomic level [15-19]. Moreover, there is a risk that persons in the most 
vulnerable populations may be less likely to benefit from available treatment re-
sources, contributing doubly to increased health inequalities. Reducing the impact of 
social inequalities is one of the challenges that industrialised countries need to re-
spond to, for health in general, and for HIV in particular. 
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2.2. Socioeconomic vulnerability and HIV 
2.2.1. Social class and HIV 
2.2.1.1. Measuring social class in health research 
Social class is a complex phenomenon and its characterisation and measure-
ment has been a debated issue within health sciences. Different variables have been 
used as proxies or best representatives of social class. 
Educational level is one of the most widely used variable because it has been 
shown to be a good approximation, especially with regard to psychosocial and behav-
ioural factors associated with social class [20-22], and when the study populations is 
comprised of young adults [23, 24]. It also has the advantage of being easy to define 
and obtain, and of being relatively stable; whereas others, such as employment status, 
are more likely to change over time and are harder to collect in the context of observa-
tional cohorts. On the other hand, educational level faces some limitations that need 
to be accounted for, such as a narrower variation span compared to other variables 
like income or wealth, and its inability to capture further changes in economic well-
being in adulthood [25-27]. Finally, education curriculum varies greatly from one coun-
try to another, making it difficult to establish comparisons between people of different 
origins and in different settings. 
Socioeconomic characteristics, like social class, ethnic origin or marital status 
have been associated with a poorer health status and with a higher mortality in per-
sons affected by chronic diseases [28-30]. Studies in Europe have shown a widening 
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inequality gap in mortality by educational level over the last decades, despite expan-
sion of the welfare state [31, 32].  
2.2.1.2. Social class and vulnerability to HIV 
The HIV epidemic in the industrialised countries appears to have shifted to-
wards the more socially vulnerable population [28]. Vulnerability to HIV can translate 
into higher incidence of infection, but it is also possible that persons in the most vul-
nerable populations may be less likely to benefit from available diagnostic and treat-
ment resources. Delayed diagnosis, worse access to treatment, limited effectiveness of 
available therapies and worse disease progression (i.e., higher incidence of AIDS and 
higher mortality), are ways in which inequalities may be expressed.  
Different studies have found association of low socioeconomic level with higher 
rates of mortality in HIV patients[33-38], although all were performed before 1999 and 
on seroprevalent subjects. Potential causes have been pointed out, including different 
disease stage at diagnosis and at treatment initiation, inequalities in access to HAART, 
the type of care and drugs prescribed, adherence to treatment or associated co-
morbidity, particularly in the case of latent tuberculosis and hepatitis C virus infections. 
For all these reasons Dray-Spira et al.[28] argue that the benefits of the most 
recent advances in HIV infection management may differ among groups of patients 
independently of their HIV-related clinical characteristics, and this can lead to inequali-
ties in the consequences of disease in settings where HAART is widely used. 
A recent study conducted in the CoRIS cohort [39] has found association of low 
educational level with a higher risk of delayed diagnosis, of delayed HAART initiation 
and a worse virological and immunological response to treatment which could partially 
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explain the higher mortality. However, it found no differences in delayed initiation of 
treatment (defined as CD4 count below 200 cells/µl at HAART initiation) by educational 
level in the group of patients timely diagnosed, pointing HIV diagnosis as the bottle-
neck to timely access to treatment. So the existence of specific barriers to access 
treatment, independently of barriers to HIV diagnosis, in the low socioeconomic strata 
is still to be clarified. The few studies that have included educational level as an ex-
planatory variable for progression to AIDS have yielded contradictory results [38, 40, 
41].   
2.2.2. Migration background and HIV  
2.2.2.1. Introduction to the migration phenomenon  
The United Nations defines a migrant as “any person who lives temporarily or 
permanently in a country where he or she was not born, and has acquired significant 
social ties to this country”. However the definition of “migration” or “migrant” has 
been highly discussed and no authoritative definition has been put forward. This re-
flects the complexity of the multidimensional migratory phenomena and the difficul-
ties that arise from the first moment when trying to study it. 
According to figures from the International Organization for Migration[42] the 
number of migrants at the global level has increased significantly in the last decade, to 
reach an estimated 214 million people by 2010, 3.1% of the world’s population and 
9.5% of the European Union’s. Poverty, the search for economic improvement and 
better standards of living are significant drivers. The majority of migrants originate 
from developing countries and move to developed countries whose economies de-
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mand labour that cannot be met by the local workforce. In the last 10 years, the edu-
cation sector has also become a major driver for mobility. 
In the European Union, non-EU immigrants are made up fairly equally of citi-
zens of European non-EU countries, Asian, American and African countries, with each 
comprising between 13% and 16% of the total[43]. However, their distribution be-
tween countries is uneven, with subjects from particular origins concentrating in spe-
cific countries. Factors related to the historical and economic relations between coun-
tries and the colonial past play an important role in shaping the specific migration pro-
file in different countries [5, 44]. 
Compared to other European countries, Spain only started to receive significant 
economic immigration in the 21st Century, and the number of migrants living in Spain 
rose 5-fold from the year 2000 to 2010. Excluding people from the European Union 
and North America, migrants represent 8.8% of the Spanish population. The migration 
profile in Spain also differs from its neighbouring countries, with the largest share of 
economic migrants coming from Latin America and the Spanish-speaking Caribbean 
(LAC), who have virtually no language barriers and a smaller cultural distance than mi-
grants from other regions. Sub-Saharan Africans (SSA) represent a small proportion of 
migrants in Spain[45], unlike other European countries in which SSA are one of the 
largest shares of economic migrants. 
2.2.2.2. Socio-economic vulnerability of migrants  
Migration involves a process that can be traumatic for individuals, even under 
the best of circumstances. The migrating person leaves behind a social network and a 
family, a full set of learned values, social rules and behavioural patterns, and arrives 
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into an alien culture which works under different coordinates. Moreover, this arrival 
usually brings along a loss of social status in the host country, stigma and discrimina-
tion. Socioeconomic conditions after arrival can also be precarious, especially in the 
group of undocumented migrants. Stressors like unemployment or poor working con-
ditions, poverty, or legal circumstances can negatively affect migrants. This situation 
has been further worsened by the economic crisis during the last years. In Spain, at the 
end of 2007, 12.4% of immigrants were unemployed, compared with 7.9% of native-
born Spaniards, but, by mid-2010, those figures had gone up to 30.2% and 18.1%, re-
spectively[42]. 
All these circumstances make it necessary to study migrants from the perspec-
tive of social inequality, and to focus on the impact that this may have on their physical 
and psychological health. Migration involves several stages, each of which presents 
strategic opportunities for prevention and disease control. There is a pre-entry phase, 
where a migrant’s health reflects the disease profile of his or her country of origin. 
There is then a transitional phase, where the process of moving, sometimes through 
intermediate countries, can influence a migrant’s health[46]. Finally, there is a post-
entry phase, where the process of adapting to working and living conditions in the host 
country can also influence a migrant’s health. Migrants are often confronted with poor 
social support and discrimination in host countries which, together with language, cul-
tural or legal barriers to health care can have a negative impact on their health, even in 
universal health care contexts, such as the Spanish one. 
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The health of migrant populations is a fundamental aspect for social integra-
tion, public health policies and health services planning and delivery, as expressed in 
recent EU policy documents[44]. 
2.2.2.3. Migrants as a most-at-risk population for HIV/AIDS 
Migration and social exclusion make migrants highly vulnerable to HIV/AIDS 
and their related complications[47-49]. As an ECDC Report on HIV epidemiology in mi-
grant populations in Europe  points out, migrants, largely from Sub-Saharan Africa, 
represent a considerable and growing proportion of both AIDS cases and HIV infections 
reported in the 27 EU countries plus Norway and Iceland during 1999– 2006[5]. Al-
though the proportions of migrants from Sub-Saharan Africa among heterosexual and 
mother-to-child HIV transmission reports are very high, a significant percentage of di-
agnoses in men who have sex with men are also made up of migrants, largely from 
Western Europe, Latin America and the Caribbean. The contribution of migrant popu-
lations to the AIDS and HIV epidemics is notably higher among female reports, high-
lighting the feminisation of the HIV/AIDS migrant epidemic in Europe, in contrast to 
the largely male autochthonous HIV epidemics.  
Regarding Spain, several information sources document the increasing repre-
sentation of migrant population in the Spanish HIV/AIDS epidemic[50]. According to 
SINIVIH data, in Spain in the year 2010, 38.4% of the new HIV diagnoses were in people 
who originated from countries different from Spain. The most common origin was 
Latin America and the Caribbean, comprising 21.4% of all diagnosis followed by an 
8.0% of Sub-Saharan Africans[12], a unique pattern within the EU where SSA account 
by far for the largest proportion of new HIV diagnoses among migrants[3, 5, 50].The 
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percentage of migrants was larger among women and in heterosexually transmitted 
cases, where more than 50% of diagnoses were from non-Spanish origin. In each of the 
migrant groups the HIV epidemic greatly reflects the prevalent transmission patterns 
in their countries of origin. Latin Americans were infected through sex between men in 
59% of cases, compared to Sub-Saharan Africans in whom 84% of new diagnoses had 
been infected through heterosexual intercourse [12].  
Information on specific HIV prevalence in migrants in Spain is scarce. A study in 
patients who attended a sexually transmitted infections clinic to voluntarily take an 
HIV test, found higher HIV prevalence in migrants from Sub-Saharan Africa and Latin 
America, compared to Spanish population[51], as other studies have also pointed 
out[52]. This same study group found that the excess prevalence depended on the 
region of origin and the specific risk for HIV infection. Compared to Spaniards, preva-
lence of HIV was 4 times higher in Latin American men who have sex with men (MSM), 
and 9.4 times and 19.3 times higher, respectively, in Latin American and Sub-Saharan 
African heterosexual males. Regarding heterosexual women, the higher prevalence 
was found in Sub-Saharan Africans (16.9 times more) and North Africans (15.3 times 
more) [53].  
One relevant aspect is whether higher HIV prevalence in migrants is explained 
because they are already infected on arrival, or because they are at a higher risk of 
infection once in the host country. This question has been extremely controversial and 
has favoured racist reactions to the HIV epidemic in migrants. However, it is very rele-
vant from the Public Health perspective, as it would mean a failure of prevention 
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strategies in this group, and would point out the need to reinforce access to informa-
tion and prevention, together with improving access to HIV testing.  
It is a fact that migrants coming from countries with generalised epidemics, 
mainly Sub-Saharan Africa, as a group, arrive with a prevalence of HIV more similar to 
their countries of origin than to the host country[54].  
However, several studies have pointed out that once in Europe, they would be 
experiencing a higher risk of infection than native-born population, either when they 
travel to their countries for visiting friends and relatives[55], or in the host country[56-
58]. In Spain, a study in people who visited a network of 19 STI clinics between 2003 
and 2004 and who performed repeated HIV testing found incidence rates of new HIV 
diagnosis were 8 times higher in Sub-Saharan Africans compared to Spaniards, and 2.7 
times higher in Easter Europeans, with no difference for other groups of migrants[59]. 
For 25% of patients the most probable country of infection was their country of origin, 
with a median stay in Spain of 7 months; 33% probably would have acquired their in-
fection in Spain, where they had been living a median of 48 months; for 42% the likely 
country of infection could not be determined[59, 60]. 
All these figures show the fact that migrants are a population that is being dis-
proportionately hit by the HIV epidemic and that they comprise a highly heterogene-
ous group who suffer very distinct epidemics, making it necessary to study migrant 
groups independently. 
2.2.2.4. Other aspects of HIV vulnerability in migrants 
Apart from the higher rates of HIV infection in migrants, other aspects of in-
creased vulnerability can be described regarding HIV. As reported by several studies 
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and information sources, migrants tend to be diagnosed in later stages compared to 
the native population[61-63]. In Spain, delayed diagnosis defined as a CD4 count of 
less than 350 cells/µl, was experienced in 42% of new HIV diagnosis in native Spaniards 
as of 2010, but was higher for most migrant groups, reaching up to 49% in the case of 
Latin Americans and 61% in Sub-Saharan Africans[12]. Risk of delayed diagnosis in mi-
grants compared to autochthonous population has been found to be higher in cohorts 
studies in Spain, but has not been estimated specifically for the different migrant 
groups[50, 63]. 
Delayed initiation of treatment has also not been studied in Spain in different 
migrant groups, although studies under different designs have found a similar need 
and access to treatment for migrants as a whole [52, 64, 65]. Until year 2012, the 
Spanish health care system has been de facto universal: almost every patient is enti-
tled to receive medical care and antiretroviral treatment, and those who are not, 
namely the migrants of uncertain status without any official identification, effectively 
access through the NGO network. So it would be expected that no barriers exist for 
migrants to access treatment, but this hypothesis has not been properly contrasted 
across the different migrant groups. 
Regarding prognosis of HIV infection, the majority of publications in Europe 
have shown no major differences in response to antiretroviral treatment (ART), risk of 
AIDS or survival in immigrants, although discordant results have been found regarding 
immunological response to treatment [66-77]. However, most studies in Europe have 
focused on Sub-Saharan African population, while risk of AIDS and survival in Latin 
Americans has not been studied other than in the United States. In Spain, no cohort 
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studies have focused on studying the risk of AIDS or death in migrants from different 
regions of origin compared to the native population[64]. 
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2.3. Cohorts of HIV infected subjects and their 
role in research 
2.3.1. Definition and classification 
Cohort studies are observational studies where a group of patients, free from 
an event of interest, are recruited and followed up over time to observe the occur-
rence of the event. Cohort studies make it possible to analyse the occurrence of one or 
several events or outcomes in subjects who have been under one or several exposure 
variables, and whose assignment was not randomized [78, 79]. Cohort studies have 
been fundamental for describing the natural history of HIV and are the most suitable 
design to study the effect of different exposures over HIV disease progression.  
Among the observational studies, cohort design is also the most sound for 
causal inference. In experimental studies exposure is assigned in a randomized way, 
and if the sample is large enough, randomization ensures that exposed and unexposed 
subjects are comparable in all characteristics except the exposition whose effect is 
under analysis. This is the basis of a randomized clinical trial, the gold standard design 
for causal inference in health sciences. However, experimental studies are limited to 
exposures that are of a nature that can be controlled and which is ethically correct to 
randomise. Other drawbacks are that they operate under a controlled environment, 
select subjects with restrictive inclusion criteria, and are under the volunteer bias (sub-
jects who self-select to participate in trials are often healthier than the average). This 
limits the external validity of clinical trials. Cohorts operate under real conditions, 
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which means that expositions are assigned according to medical practice, and so causal 
inference is not straightforward, but the profile of patients who participate are more 
representative of the real target population. 
Cohorts can be classified according to a number of characteristics, as defined by 
Jarrín et al.[78], but one of the more relevant classifications in HIV cohorts depends on 
the characteristics of the subjects included in the study and differentiate between se-
roconverter and seroprevalent cohorts.  
Seroconverter cohorts include subjects whose date of HIV infection is known or 
can be estimated with acceptable accuracy. As described by Jarrín et al., seroconverter 
cohorts can be further classified into incident cohorts, if they identify seronegative 
individuals and follow them up over time to observe their seroconversion; or prevalent 
cohorts with known date of infection, if they identify HIV positive subjects and assess 
their seroconversion date retrospectively based on previous information, generally a 
previous negative test or an undetermined Western Blot.[80]. On the other hand sero-
prevalent cohorts include subjects who are HIV-positive at recruitment but there is no 
information available on when they got infected.  
2.3.2. Analytical approaches for cohort data 
2.3.2.1. Statistical Methods for cohort analysis 
Normally, in a cohort study analysis the main interest will be in estimating the 
incidence rate of a given event, or the time it takes a certain percentage of patients to 
be affected by it and/or in measuring the effect of a given set of variables over the risk 
of the event. 
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Classical statistical methods used to respond to these questions are Kaplan-
Meier method, which allows us to estimate the survival curve or its complementary, 
the cumulative incidence curve; log-rank test, used to compare survival curves over 
different levels of an explanatory variable; and Cox proportional hazard models, to 
estimate the effect of a set of variables over the hazard, i.e. over the instant risk of 
suffering the event. Due to correspondence between survival and hazard functions, 
results of Cox proportional hazard models can be interpreted in terms of effect over 
cumulative incidence of the event.  
However, these methods are limited in several situations, two of them relevant 
for the analysis performed in this Doctoral Thesis: in the presence of competing events 
and in the presence of informative censoring, as will be discussed below. Other poten-
tial biases and methodological approaches are discussed under the following headings. 
2.3.2.2. Common biases and analytical approaches in cohort 
studies 
In an ideal setting, researchers would follow a cohort of patients for an infinite 
time and thus would be able to observe the occurrence of the event of interest in 
every subject in the study. In a real setting, the time under observation is finite, and 
events may not occur within the observed period, producing a so called right censor-
ing. There are three main reasons for right censoring: administrative censoring (i.e. 
end of the study), loss to follow-up (LTFU) of the patient, or occurrence of a secondary 
event that prevents the event of interest from happening (i.e. death of the patient 
prevents him/her from being diagnosed AIDS or being prescribed treatment). 
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Most methods for statistical analysis, like the Kaplan-Meier estimate or the Cox 
proportional hazards model, work under the assumption that time to event and time 
to censoring are independent. In the first case, where subjects are censored at the 
date of the end of the study, we can easily assume that the end of the study is not as-
sociated to the event of interest. But in the other two situations, independence can be 
harder to assume. 
Losses to follow-up are one of the most important sources of bias in cohort 
studies. If subjects are lost to follow-up randomly, for reasons not associated to the 
event of interest, those individuals who remain in the study can be assumed to repre-
sent missing subjects. But it is possible that subjects who leave the study are different 
from those who remain. For example, if people with a slower disease progression hap-
pen to miss follow-up visits while those with a faster disease progression are more 
adherent to clinical visits, those who experience the event would be over-represented 
and we would overestimate incidence. Several HIV cohorts have described that sub-
jects lost to follow-up have better clinical characteristics[81, 82], confirming this situa-
tion. If in addition, some variable of interest, like the country of origin of the pa-
tient[81, 82] determine different rates of losses to follow up, we can introduce a bias 
by not taking into account this informative censoring. Several methods have been de-
scribed to deal with this possible source of bias. 
One method is to weight each observation by the probability of remaining un-
censored given a set of explanatory variables. For that purpose and as described by 
Fewell et al.[83] each patient has to be split up into as many registers in the database 
as months is under observation. The cumulative number of months under follow-up at 
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every consecutive month (‘month’), together with splines or another function of 
‘month’ are introduced in the model to allow for a non-linear relation between out-
come and follow-up time. A pooled logistic regression is then performed, thus simulat-
ing a Cox model where the estimated function of ‘month’ is equal to the baseline haz-
ard function.  
For each particular month, probability of not being LTFU is estimated using a 
logistic regression where baseline and current month variables are taken into account, 
so that we allow for past and present clinical conditions, markers, treatment, etc. to 
influence the probability of not leaving the study. Any other fixed variables such as 
educational level, sex or region of origin, among others, can also be introduced into 
the model. The inverse of this probability can be used to make each patient-month 
under observation represent those patient-months of similar characteristics which 
were not observed due to censoring. However, use of stabilised weights is recom-
mended by Cole S.R. and Hernán M.A.[84]. Stabilised weights are calculated as the 
probability of being not LTFU estimated out from a model that takes only into account 
baseline variables, divided by the probability of being not LTFU derived from a model 
that also considers time-varying variables updated for each particular month. These 
stabilised weights are then introduced in the pooled logistic regression considering 
each patient as a cluster. 
Another usual option in cohorts is to cross cohort patients with AIDS and death 
registries, if available. This allows retrieving information about events of interest in 
patients that were LTFU. Assumptions have to be made that registries are complete, 
that patients not appearing in the registry are free from the event, and that every pa-
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tient has the same probability to appear in the registry, or otherwise a bias can be in-
troduced.  If this strategy is used, follow-up of every patient LTFU has to be artificially 
expanded up to the closing date of the registry. Otherwise, patients with the event 
would be represented, but not the free-of-event time of patients not experiencing the 
event. Generally, the last one or two years before the closing date of the registry are 
not considered to allow for the usual delays in notification.  
As previously mentioned, the third reason for right censoring is the presence of 
a competing event, an event that, when occurring, prevents the event of interest from 
happening. Again, if there is no association between the time to the event of interest 
and the time to a competing event, those who experience the competing event would 
virtually remain represented by those who do not, and a standard analysis which cen-
sors patients who experience a competing event, would give us an unbiased estimate 
of the incidence rate in a counterfactual world where nobody experienced the compet-
ing event. But this assumption cannot be tested in the observed data and in this situa-
tion, Kaplan Meier estimates can only be interpreted as the instant probability of ex-
periencing the event conditioned to the probability of being alive and event-free at 
that instant. Also, as argued by Putter at al.[85], a subject that is censored because of 
failure from a competing risk will with certainty not experience the event of interest. 
Since subjects that will never fail are treated as if they could fail (they are censored), 
the Kaplan–Meier function overestimates the probability of failure (and hence under-
estimates the corresponding survival probability). 
Obtaining an unbiased estimation of the cumulative incidence of a certain 
event and its association with a range of independent variables, acknowledging the 
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existence of competing events, requires alternative methods. Putter et al. described a 
method to estimate cumulative incidence in the presence of competing events called 
the multiple decrements method[85], that estimates a cumulative incidence curve for 
the event of interest and each of the competing events; And Fine and Gray[86] de-
scribed a method to model the effect of a given covariate over the sub-distribution of 
the risk of the event of interest. In practical terms, both methods are based in a simple 
idea: in a world of existing competing events, those individuals who experience the 
competing event will never experience the event of interest, so they are not censored, 
but are kept “alive” in the data set as event-free follow-up time. Results from these 
models can be interpreted directly as effect over the cumulative incidence, or risk of 
the event.  
2.3.2.3. Seroconverter cohorts: strengths and potential biases 
Studies of seroconverters are the best way to investigate the natural history of 
HIV[87], as they have information on the exact origin of risk, i.e. when the HIV infec-
tion took place. However, they may need a longer follow-up time to observe events 
that can take a long time to occur, as is the case of AIDS incubation period, which was 
estimated to be around 10 years in the absence of treatment[88, 89]. 
Also, the profile of patients recruited in a seroconverter cohort is very specific 
and does not represent all the HIV-infected population. Subjects who undergo HIV 
testing repeatedly, and thus are self-perceived to be at risk of infection, are at an in-
creased probability of being recruited into a seroconverter cohort. Also, the require-
ments to be a seroconverter exclude subjects who experience diagnostic delay. This 
type of cohort design therefore ignores patients who may have either a low self-
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perceived risk or experience barriers to access testing. This is known as the serocon-
verter bias and limits the external validity of these studies. Also because heterosexually 
infected individuals tend to have a lower risk perception, they are often underrepre-
sented in these cohorts, as often are women, so studies that aim at exploring the in-
fluence of any of these variables would probably find small sample sizes under this 
design.  
From the analysis perspective, it is important to define if the seroconverter co-
hort has a prevalent design –where HIV positive subjects are recruited and the infec-
tion date is assessed retrospectively- because they are affected by the so called left 
truncation or delayed entry. This means that the event that marks the risk origin (in 
our case, the date of HIV infection) is not observed, but the patient is only recruited 
and starts to be observed after some time after infection has passed. During the time 
after HIV infection and before cohort recruitment, some patients could experience 
adverse events or die. This can lead to a survivor bias, as only subjects who survive 
long enough have the opportunity of being recruited into the cohort; but those who 
died too soon to be identified in the cohort and recruited are not represented in the 
dataset. So if we analysed data directly taking into account only the time from HIV in-
fection to the outcome, we would be underestimating its incidence, as subjects with 
faster occurrence of the event are missing.  
To minimize this source of bias, it is necessary to incorporate methods that cor-
rect for the fact that some of the time since risk origin was in fact not observed. Under 
this method, patients only start to contribute to cumulative incidence calculation since 
the date they start their follow-up in the cohort. However, time since HIV infection 
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(risk origin) is also considered, in a way that subjects are always compared with sub-
jects with similar total duration of infection [90]. 
Finally, other possible bias can occur under this design since we estimate the 
date of seroconversion based on the existence of a previous negative test. The exact 
date of seroconversion will be comprised between this last negative and the first posi-
tive test, generating a so called interval censored event. Usually, the middle point be-
tween both tests is estimated to be the date when the subject got infected, but this 
assumes every subject has a constant risk during the interval and that subjects perform 
HIV test with similar frequency, independently of their risk. As described by Law et 
al.[91] these facts don’t affect liability as long as only intervals between both tests of 3 
years or less are considered. Also, it has been pointed out that testing dates need to be 
documented, to avoid a memory bias in non-documented seroconverters[90]. 
2.3.2.4. Seroprevalent cohorts: strengths and potential biases 
Seroprevalent cohorts yield less accurate estimates of the natural history of 
disease, as no direct information exists on the date when subjects got infected by HIV. 
However, they have several advantages. As included subjects have normally gone 
through part of the natural history of disease, follow-up time needed to observe 
events is generally shorter and recruiting subjects is easier, so they are more efficient 
studies. Also, they do not tend to include a special patient profile, and inclusion criteria 
are generally less restrictive, so included patients are more varied and representative 
of the whole HIV epidemic and external validity is improved.  
The main source of bias in seroprevalent cohorts relates to the fact that the 
origin of risk (i.e. HIV infection) is unknown [92], leading to a so called left censoring. If 
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we analysed time from recruitment in the cohort to the outcome, we can introduce a 
bias if subjects of a certain characteristic –for example, being from a non-Spanish ori-
gin- is related to being recruited in more advanced stages of disease. In this case, risk 
of suffering the outcome would appear higher in this group even if there was no real 
difference. The most accepted solution to minimize this problem is to adjust the model 
by a progression marker measured at recruitment that would account for duration of 
infection, normally, CD4 count and viral load (VL). 
Finally, for studies whose objective is to analyse response to treatment –and so 
the risk origin would be treatment initiation- a seroprevalent cohort composed of anti-
retroviral naïve individuals who start treatment over their follow-up is the most effi-
cient and the ideal design, as it allows us to observe the exact risk origin. In this par-
ticular case, seroconverter cohorts do not offer any advantages, but in fact only the 
inconveniences associated with this type of design. 
2.3.2.5. Studying migrants: methodological considerations  
Some considerations have already been made about problems arising when 
working with migrants. For example, the fact that they show higher rates of loss to 
follow-up in cohort studies makes it necessary to account for this informative censor-
ing, preferably through IPW. Crossing with registries may not be such a good option in 
this case, as migrants are more likely to return to their home country or further immi-
grate to another country in Europe, so they would be less likely to appear in Spanish 
AIDS and death registries. Crossing with national registries would then underestimate 
AIDS and death risk in this group. 
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There are also two well-described phenomena in studies involving migrants 
that tend to result in lower mortality rates in migrants compared to host country popu-
lation: the healthy migrant effect and the salmon bias. The first one refers to the fact 
that, at the time of arrival into the country of emigration, most migrants tend to have 
better health than host country populations. This phenomenon is a particular form of 
selection bias attributed to the various processes that labour migrants undergo before 
coming into the country of destination. Since most people go to another country ex-
pecting to work, those who most frequently migrate are the fittest, best able to survive 
the journey and pass the medical examinations they may have to undergo. This effect 
could account for better health and lower mortality in migrants, but it is not a bias, as 
differences found are in fact present. With notable exceptions, immigrants’ and na-
tionals’ health patterns tend to converge after some years after migration and, for 
some health conditions, immigrants fare worse[93-95].  
On the other hand, the so-called salmon bias refers to the fact that migrants 
may want to return to their home countries when feeling chronically and/or severely 
sick, and can result in artificial estimates of a lower mortality in migrants even in the 
case where no differences existed. It may be explained by a hampered ability to re-
main employed in adverse health conditions, the search for a context of better social 
and family support to cope with disease, or simply the desire to die in one’s birthplace. 
This would imply that migrants who abandon the country (and the study) will be those 
in worse health conditions, and thus the most likely to suffer a health event or to de-
cease, which produces an underestimation of risk [96, 97].  
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2.3.2.6. On exposure variables in cohort studies 
In HIV cohort studies, we are able to measure a number of variables at recruit-
ment and during follow-up. From the analysis perspective, it is important to notice the 
difference between fixed variables and time-dependent variables. 
Fixed variables are either variables that don’t change over time like sex, region 
of origin, likely route of HIV infection, or delayed diagnosis or variables that can vary 
with time, but that are however collected at recruitment and treated as fixed, such as 
educational level, CDC stage, CD4 count and Viral Load at recruitment, etc. 
On the contrary, we would like to allow some variables to change with time, as 
CD4 count and Viral Load, antiretroviral treatment, AIDS defining illnesses suffered, 
etc. These variables that change overtime in each individual are known as internal 
varying variables[78]. But variables can also change over time in the same way for all 
the subjects in the study. For example, in HIV, the generalization of HAART in 1997 
marked a prognostic turnover and completely changed the natural history of HIV infec-
tion, and so the risk of developing AIDS and death for patients before 1997 was much 
higher than after this date. Calendar period can be used as a proxy of HAART availabil-
ity, and in this case it is called an external varying covariate. 
2.3.2.7. Individual and population effectiveness 
The diffusion of HAART has drastically slowed down the rate of progression 
from HIV infection to AIDS and death, transforming HIV into a chronic disease. Most 
conclusive results on treatment efficacy have been obtained trough clinical trials, 
which operate under ideal conditions. However, the measurement of the effect of a 
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given treatment under real life conditions and routine medical practice gives comple-
mentary information and is called effectiveness. Two different effectiveness measures 
have been defined by Muñoz et al. [98]  
Individual effectiveness analyses try to replicate a randomized clinical trial out 
of observational data, and compares outcomes in treated vs. non treated subjects, 
adjusting for any characteristics that are associated with receiving vs. not receiving 
treatment to avoid an indication bias. 
On the other hand, population effectiveness analyses show the benefits of ex-
isting treatments when they penetrate a given population, and are especially impor-
tant to analyse its real impact. It compares a population where treatments are avail-
able and where subjects who need treatment will receive it, to a population where 
treatment is not available for anybody, even for those who may need it. Considering 
calendar period as an explanatory variable, as previously mentioned, we can compare 
AIDS and death incidence in the population before 1997 with that of the population 
after 1997, which will yield us results on population effectiveness of HAART.  
In this case, an individual can be under follow-up during both periods and thus 
be present in both populations that are being compared. Using the calendar period as 
an explanatory variable means we need to split patients up and assign observed pa-
tient-time to the corresponding period, ignoring the time observed outside the period, 
but taking into account the total duration of infection, so that comparisons are always 
established between patients with same length of infection. The result would be simi-
lar to performing an administrative censoring at the end of each period and a left trun-
cation in the starting point of the next one. 
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Monitoring equal access to resources and treatment effectiveness in different 
socioeconomic groups is fundamental to ensure that appropriate interventions are put 
in place and respond to specific challenges, especially in the context of a universal, free 
health care system like the one existing in Spain.  
Despite several studies have been performed addressing the issue of social ine-
qualities in HIV, some clues are missing to better characterise the influence of socio-
economic determinants over the complex dimensions of HIV disease. Due to its rele-
vance and its ability to capture important aspects of socioeconomic level, in this doc-
toral thesis we decided to focus on studying the influence of educational level and 
country of origin.  
However, a first approach was performed to the study subject, evaluating a 
wide range of socioeconomic and demographic variables in a predictive approach over 
risk of HIV progression. A cohort in Madrid was chosen for this study outcome, as a 
previous similar study had been carried out with 1999 data [40], and so we would be 
able to fulfil our objective while contrasting or confirming data from previous epidemic 
stages. 
Regarding the effect of educational level over HIV-related outcomes, previously 
published articles point out the existence of inequalities in different educational 
groups, specifically a higher mortality in people of low educational level. However, all 
studies have been carried out in seroprevalent subjects, with their intrinsic limitations 
when studying natural history of disease. Also, the few studies that have included edu-
cational level as an explanatory variable for progression to AIDS, all of which were 
conducted in the pre-HAART era, have yielded contradictory results. On the other 
hand, recent studies have shown a higher risk of delayed diagnosis and delayed initia-
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tion of treatment in subjects of low educational level. However, whether a higher risk 
of delayed initiation of treatment actually exists in those timely diagnosed is still to be 
clarified. To address these issues, we analyzed a national seroconverter cohort, which 
is the best design to study natural history of disease and which includes subjects that, 
by definition, are not subjected to delayed diagnosis. 
Another source of socioeconomic inequalities, as argued in the introduction, is 
the migratory status. Migrants are a most-at-risk population regarding HIV/AIDS and 
studies in Europe have shown a higher prevalence and a higher risk of delayed diagno-
sis in this group. However, in Spain, no cohort studies have focused on estimating the 
risk of delayed diagnosis, of delayed access to treatment and risk of AIDS and death in 
migrants of different regions of origin. Also, little data exists in our context regarding 
response to treatment of HIV-infected migrants according to specific regions of origin. 
For all these reasons we decided to study migrants from different origins and their risk 
of a wide set of HIV-related end points. For this purpose, we decided to analyse a se-
roprevalent cohort, which is a more efficient design and provided us with an appropri-
ate sample size of Sub-Saharan Africans and Latin Americans. Other regions of origin 
were represented in too small numbers and could not be studied. 
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Objective 1: To identify socioeconomic and demographic variables that predict disease 
progression since HIV seroconversion in Madrid (Spain), before and after the generali-
sation of HAART. 
Objective 1.1: To evaluate association of age, sex, educational level, transmis-
sion category, and region of origin with HIV disease progression to AIDS and all-
cause mortality, before and after the generalisation of HAART. 
Objective 2: To estimate the effect of educational level over HIV-disease progression 
since HIV seroconversion and access to treatment at different periods of the HIV epi-
demic in Spain. 
Objective 2.1: To estimate the effect of educational level over risk of AIDS at 
different periods of the HIV epidemic in Spain. 
Objective 2.2: To estimate the effect of educational level over survival at dif-
ferent periods of the HIV epidemic in Spain. 
Objective 2.3: To estimate the effect of educational level over time to HAART 
requirement and time to HAART initiation as proxies for access to treatment in 
the period after 1997 in Spain. 
Objective 3: To analyse key HIV-related outcomes for migrants originating from Latin 
America and Sub-Saharan Africa living in Spain compared to the native population. 
Objective 3.1: To analyse if any differences exist by geographical origin in risk of 
delayed diagnosis of HIV infection. 
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Objective 3.2: To analyse if any differences exist by geographical origin in time 
to cART requirement and time to cART initiation as proxies for access to treat-
ment. 
Objective 3.3: To analyse if any differences exist by geographical origin in vi-
rological and immunological response to cART once initiated. 
Objective 3.4: To analyse if any differences exist by geographical origin in risks 
of AIDS and overall survival. 
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5.1. Methods for Objective 1 
5.1.1. Study Population 
We analysed data from the Seroconverter Madrid Cohort, whose patients have 
been identified at the “Centro Sanitario Sandoval” from 1985 onwards. Recruitment is 
still ongoing. The Centro Sanitario Sandoval is an ambulatory STD clinic and HIV screen-
ing centre whose access is open, free, and anonymous and has been a pioneering cen-
tre in HIV prevention in Madrid. HIV negative subjects are invited to come back after 6 
months for follow-up HIV tests. If they become HIV positive, patients are followed up 
in the centre until they require antiretroviral treatment and/or hospital admission. 
Patients are then referred to various hospitals in Madrid for clinical follow-up and anti-
retroviral treatment.  
In this cohort, the definition of a seroconverter was an individual aged 16 or 
over who had a negative HIV test within the 3 years before the first HIV positive test, 
or who had a positive ELISA test with an undetermined result in the Western Blot. Pa-
tients who could provide a documented HIV negative test or undetermined WB per-
formed outside the Centro Sanitario Sandoval were also included in the cohort. Com-
plete ascertainment of all seroconverters seen in the recruiting centre was carefully 
sought. The reconstruction of the cohort was done in 1997, but all people who sero-
converted before that date were selected independently from their outcome.  
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Seroconversion date was estimated as the mid-point between the last HIV 
negative and the first HIV positive tests, or the date of the undetermined WB test, as 
appropriate. Administrative censoring for this analysis was February 2009. 
5.1.2. Follow-up and variables 
Socio-demographic and epidemiological patient characteristics were collected 
upon recruitment, including age, sex, mode of HIV transmission, educational level and 
country of origin.  
Educational level was recorded in four categories: below primary education; 
primary education completed, being subjects who had finalised the compulsory educa-
tion, usually remaining on formal education until 14 years of age; secondary education, 
which included subjects who had completed high school degree or equivalent; and 
tertiary education, if the subject had completed university studies. The variable was 
grouped into two levels for this analysis: persons with a low educational level (no edu-
cation or only primary education completed) and persons with a high educational level 
(secondary or university studies completed). 
Due to the low number of subjects with heterosexual transmission, the trans-
mission category was grouped into two mutually exclusive categories: injecting drug 
users (IDU); and sexual transmission and other, which included heterosexual transmis-
sion, men who have sex with men and people with other transmission routes. 
Due to small sample size, country of origin could only be categorised into three 
regions: Spain, Latin America and the Caribbean, and other regions.  
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During the recruitment visit, clinical and analytical baseline variables were also 
collected.  
Patient’s follow-up was done according to routine medical practice and, during 
visits, any relevant clinical and analytical information was collected, along with HIV 
treatment status. Follow-up information of seroconverters was updated in the data-
base yearly, both in the recruiting centre and in the referring hospitals. For patients 
lost to follow up, cross-checks using name, surname, and date of birth were performed 
with the databases from the 12 participating hospitals within the Community of Ma-
drid.  
Patients were also cross-checked with the national AIDS registry in 2007 and 
with the national death registry from the National Institute of Statistics in 2006. Pa-
tients not appearing in the registries were assumed to be AIDS and/or death free by 
31st December 2005 and 31st December 2004 respectively, acknowledging  the usual 
reporting delays and selecting a period where completeness of the registries could be 
assumed[90]. After those dates, subjects were censored in the date of their last follow-
up visit in either the recruiting centre or the referral hospitals.  
Sensitivity analyses were performed with different censoring strategies to allow 
for different yield of the registries. The first strategy considered patients not appearing 
in the registries were event-free up to one year before the registry closing date. The 
second strategy considered registries could only be assumed as complete up to three 
years before their closing date, and censored patients as event-free on that date. The 
third strategy made no assumptions beyond the time patients were last seen on a 
5. Methods                    Susana Monge Corella 
50 
clinical follow-up visit, and thus censored every patient at their last visit. Results re-
mained largely unchanged under the different models. 
To estimate population effectiveness of HAART, calendar period was used as a 
proxy for HAART availability and introduced in the analysis as a time-changing variable 
with two categories: pre-HAART era (up to 1996) and HAART era (1997 onwards). Each 
patient contributed to the analyses with as many registries as periods at risk he/she 
contributed to the study, and patients with an equal duration of infection were com-
pared for each period. 
5.1.3. Statistical Analysis 
Characteristics of the sample were described using proportion or median (and 
Inter-quartile Range), as appropriate. Chi2 test for categorical variables and Kruskal-
Wallis test for continuous variables were used for bivariate analysis. 
A survival analysis was performed, considering seroconversion date as the on-
set of risk, but with a delayed entry (or left truncation) to the date of first HIV positive 
test in the recruiting centre, to minimize the survivor bias. A predictive step-forward 
modelling was performed to identify variables associated to cumulative risk of AIDS 
and cumulative risk of death. Independent variables assessed were sex, age at sero-
conversion, educational level, region of origin, transmission category and calendar pe-
riod under observation. No adjustment for CD4 counts or Viral Load was needed at 
baseline, as all patients were seroconverters and baseline values were very homoge-
neous. To allow the effect of variables to vary among the different calendar periods, 
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interaction between each variable in the final model and calendar period was system-
atically explored. 
Cumulative risk of all-cause mortality was calculated by Kaplan-Meier estimates 
and Cox proportional hazards model was used to assess adjusted effects of independ-
ent variables over survival, estimated through Hazard Ratios (HR).  
For cumulative risk of AIDS, death was considered as a competing event, as pa-
tients who died before being diagnosed of AIDS had no longer the opportunity of ex-
periencing the event of interest. Cumulative incidence function was therefore calcu-
lated through the multiple decrements method, and a Fine and Gray model was used 
for multivariate analysis, and resulted in estimation of the so-called sub-Hazard Ratios 
(sHR). Sensitivity analyses were performed under different assumptions of what hap-
pened to those suffering the competing event: the first strategy censored patients on 
their date of death; and the second strategy censored them at the end of the calendar 
period where they were deceased. Results did not vary under any of these assump-
tions. 
Robust methods were used for standard error estimation and statistical signifi-
cance was evaluated using Wald’s test. All analyses were carried out using Stata Soft-
ware (version 11.1, Stata Corporation, College Station, Texas). 
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5.2. Methods for Objective 2 
5.2.1. Study Population 
We analysed data from the Spanish Multicenter Study Group of Seroconverters 
(Spanish acronym GEMES), an open, prospective, multicentre cohort of HIV positive 
subjects with a known date of seroconversion. 
GEMES comprises nine individual cohorts from different recruiting centres over 
Spain: a cohort from Centres for Information and Prevention of AIDS (CIPS, by the 
Spanish acronym) in the Comunidad Valenciana located in the cities of Alicante, Cas-
tellón and Valencia; cohorts from the Centres for Prevention and Care of AIDS (CAPS) 
in the city of Barcelona; the Madrid cohort recruited in the Centro Sanitario Sandoval, 
previously described in section 5.1.1; the cohort from the Prisons Health Service in 
Barcelona; the seroconverter cohort from Navarra; the cohort of the HIV Unit in the 
Germans Trias i Pujol Hospital, in Badalona; and three Haemophilia Unit cohorts from  
Hospitals in Barcelona, Seville and Madrid.  More information on individual cohorts 
characteristics can be found in individual publications [99-102]. For the purpose of our 
analysis, patients recruited in the Haemophilia Units were excluded from the study 
population as they had been infected in a good proportion during childhood and re-
verse causality between HIV progression and educational attainment could not be 
ruled out in that case.   
A seroconverter was defined as mentioned for Objective 1 (section 5.1.1), and 
the seroconversion date was estimated in a similar way. Recruiting sites identified se-
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roconverters from 1983 onwards, both prospectively and retrospectively, so both sero-
incident and seroprevalent subjects were included as long as the necessary clinical 
information was available.  
Methods for identification of seroconverters in each individual cohort were dif-
ferent according to specific characteristics of each site, but in every case it was done 
independently of the subsequent progression of disease. Administrative censoring for 
this analysis was February 2009. 
5.2.2. Follow-up and variables 
A standardised protocol for data collection was followed by the different par-
ticipating cohorts. Baseline information was collected at recruitment date. Educational 
level was measured at cohort entry in four categories and categorised in two levels for 
analysis, in the same way as exposed for Objective 1 (section 5.1.2). HIV transmission 
route was also grouped into two categories, as done in the previous analysis. Data on 
CD4 levels and viral load at diagnosis, sex and age at time of seroconversion, patient’s 
region of origin, and the method used to estimate the date of seroconversion were 
also collected. Region of origin was not introduced in the analysis as there were too 
few subjects to create meaningful groups that could adequately account for the het-
erogeneity of the migrant population in Spain. 
Patients were followed up according to clinical practice with further collection 
of clinical, laboratory and treatment variables. Many of the recruiting centres refer 
patients to Hospital Units when they experience an AIDS-defining illness or other con-
ditions that need specialised care, or fulfil criteria to start antiretroviral treatment. 
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These patients were followed up in coordination with the referral centres or with the 
patient him/herself.  
To minimize losses to follow-up, patients were cross-matched with the National 
Registry of AIDS cases in the year 2004. Patients not appearing in the registry were 
considered AIDS-free as of 31st December 2002, leaving two washout years to correct 
for reporting delays[90]. For dates after the cross-match, only AIDS events occurring 
during clinical follow-up were registered, and those lost to follow-up were censored as 
event-free on the last date they had been seen.  Three of the six cohorts under analysis 
were cross-matched with the mortality registry of the National Statistics Institute: two 
by 2006 and one by 2008. Subjects not recorded as deceased in the registries were 
considered alive until 2 years before the closing date of the registry. After the cross-
match date and for cohorts not cross-matched, losses to follow-up were censored and 
considered alive on the date of their last visit. Sensitivity analysis were performed with 
different censoring strategies to allow for different yield of the registries, under the 
same assumptions described in section 5.1.2, and results remained largely unchanged. 
Follow-up was divided into three periods that reflected the different availability 
and changes in HAART recommendations: Years before 1996 formed the pre-HAART 
era and were used as reference for comparison; years from 1997 to 2003 were consid-
ered the first part of the HAART era, and comprised the second period for analysis; 
finally, years 2004 onwards, were considered as a third and independent period based 
the recommendation to start treatment at an earlier stage of disease and on a signifi-
cant increase in HAART efficacy. Calendar period was introduced as a time-dependent 
covariable, as exposed for Objective 1.  
Socioeconomic factors and HIV-related outcomes: Delayed diagnosis, access to treatment and disease progression 
55 
Analysed outcomes were risk of progression to AIDS, death, HAART initiation 
and HAART requirement, defined as the time until a patient reached a CD4 count un-
der 350cells/mm3 or developed an AIDS defining condition. 
5.2.3. Statistical Analysis 
The characteristics of the sample were described and nonparametric tests –
Chi2 for categorical data and Kruskal-Wallis for continuous variables- were applied to 
evaluate clinical and socio-demographic differences by educational level. Only patients 
with information on educational level were included in subsequent analysis. 
Survival analyses were conducted taking the date of seroconversion as the risk 
origin, but with delayed entry to the time of the first positive diagnosis in the recruit-
ment centre to eliminate possible survival bias. The association between the exposure 
of interest, ‘educational level’ and the various outcomes was examined in crude analy-
ses, and a multivariate analysis was carried out with an estimative strategy to adjust 
for all potential confounders, where variables that produced a change higher than 10% 
in the HR of interest were retained in the model. Proportionality of hazards assump-
tion was tested for educational level and every outcome. Interaction between educa-
tional level and the different confounding variables was tested in every model. 
To evaluate the risk of progression to AIDS, death was considered as a compet-
ing event; therefore, the cumulative incidence function was estimated by the multiple 
decrements method. To evaluate the adjusted effect of educational level on the risk of 
AIDS the Fine and Gray method was used. For overall survival, the cumulative inci-
dence function was calculated using the Kaplan-Meier method. To evaluate the ad-
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justed effect of educational level on the risk of death, Cox’s proportional hazards 
model was used to estimate the HR. 
The analysis of time to requirement of HAART and time to HAART initiation was 
restricted to persons seroconverting after 1996, time at which HAART became univer-
sally available in Spain, and each individual was censored on the date of the last visit. 
Death was considered as a competing event, and the multiple decrements method and 
the Fine and Gray model were used for respective estimations.  
Sensitivity analysis were performed under different assumptions of what hap-
pened to those suffering the competing event, as previously described in section 5.1.3,  
and results did not vary with under any of the assumptions.  
 Robust methods were used for standard error estimation, and statistical sig-
nificance was evaluated using the Wald test. All the analyses were conducted using 
Stata software (V.11.1, Stata Corporation, College Station, Texas, USA). 
Socioeconomic factors and HIV-related outcomes: Delayed diagnosis, access to treatment and disease progression 
57 
5.3. Methods for Objective 3 
5.3.1. Study Population 
We analysed data from the Cohort of the Spanish AIDS Research Network (Co-
RIS) an open, multicentre, prospective cohort of patients over 13 years-old with con-
firmed HIV infection and naïve to antiretroviral treatment at entry. CoRIS is a sero-
prevalent cohort, although seroconverter subjects can also be recruited. 
CoRIS is a national cohort under the umbrella of the Spanish AIDS Research 
Network (Spanish acronym, RIS). 31 HIV units from 28 Centres in 13 of the 17 Autono-
mous Communities of Spain participate in CoRIS. After a given Centre is included as a 
CoRIS participating site, it is required to recruit every patient who consults for the first 
time in the centre and who fulfils inclusion criteria as mentioned above. A semi-
anonymous code is given to every patient containing the first two letters of his/her 
two surnames, the birth date and the sex, so patients transferred between participat-
ing sites can be univocally identified, follow-up continued and duplicates are detected. 
Information is annually sent to the coordinating centre of the cohort to undergo sev-
eral internal quality controls. 
The CoRIS cohort began in 2004 and recruitment is ongoing. Ethics approval 
was obtained and every patient signed a written informed consent. English and French 
versions were available to encourage participation of migrants with poor knowledge of 
Spanish. Detailed descriptions of the cohort can be found in the literature[81, 103]. 
Administrative censoring for this study was October 2010. 
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5.3.2. Follow-up and variables 
All CoRIS sites record variables in a standardised way following the cohort pro-
tocol and data quality control procedures are performed every year. Different socio-
demographical and epidemiological variables are collected at recruitment including 
sex, age, most probable route of HIV transmission, educational level, self-referred re-
gion of origin, CDC Stage, date of HIV diagnosis and previous negative tests if available, 
along with other clinical and analytical baseline data.  
Patients are followed up according to routine clinical practice, and relevant in-
formation on CD4 counts and Viral Load (VL) is recorded in each visit, along with clini-
cal, analytical and treatment information. Follow-up of patients ends when the patient 
dies, or when the patient changes his follow-up to a centre that does not belong to 
CoRIS and thus is lost to follow-up. In this case, no cross-match with registries was per-
formed, to avoid bias associated with the different probability of appearing for the 
different regions of origin, so patients were censored in their last follow-up visit in a 
CoRIS centre.  
To characterise access to ART and prognosis of HIV infection across different 
regions of origin, we analysed seven different outcomes: HIV diagnostic delay, time to 
ART requirement, time to ART initiation, immunological and virological response to 
ART, time to AIDS diagnosis and time to death. 
Diagnostic delay (DD) was defined as having a CD4 count below 350cells/mm3 
or an AIDS-defining illness in the first year following HIV diagnosis[13, 63], so only pa-
tients with an available CD4 count within that period could contribute to the denomi-
nator. 
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ART requirement was defined according to minimum criteria for ART initiation 
in Spain throughout the study period[104]; that is, CD4 count ≤350cells/mm3 or an 
AIDS diagnosis. These criteria have been expanded in the last years to include new 
treatment indications. These were not included in the analysis, and thus there are a 
proportion of subjects initiating treatment before fulfilling initiation criteria. Date of 
HAART initiation was considered to be the date where the first antiretroviral drug was 
prescribed to the patient.  
For analysis of immunological and virological response to treatment, included 
patients were those who had at least one CD4 count of any value, or a VL measure-
ment over 50copies/ml, respectively, in the 6 months prior to ART initiation and at 
least 2 post-ART determinations, one within the first year after ART initiation. Time to 
virological response was analysed as time from ART initiation until the first of two con-
secutive VLs was below 50copies/ml; and immunological response was the first of two 
consecutive CD4 counts of at least 100cells/mm3 higher than pre-ART determination. 
Patients not experiencing the event were censored in their last CD4 or VL assessment 
respectively. 
5.3.3. Statistical Analysis 
Only patients originating from Spain, Latin America and the Caribbean (LAC) or 
Sub-Saharan Africa (SSA) were included in the analysis. Chi2 and Kruskal-Wallis tests 
were used to evaluate differences according to the region of origin. The association 
between the exposure of interest, ‘region of origin’ and the various outcomes was ex-
amined in crude analyses, and a multivariate analysis was carried out with an estima-
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tive strategy to adjust for all potential confounders, where variables that produced a 
change higher than 10% in the HR of interest were retained in the model.  
For analysis of Delayed Diagnosis (DD), a multivariate logistic regression was fit-
ted to analyse the association between region of origin and DD after adjustment for 
any confounding variables. 
To assess differences in ART requirement across regions, a survival analysis was 
performed, taking into account that death and initiating ART were competing events 
for ART requirement, as those initiating ART could not experience the event of fulfilling 
criteria to start ART for the first time. Thus patients for this analysis were censored at 
the date of the last follow-up visit or at date of ART initiation, whatever came first, and 
a multivariate Fine and Gray regression was fitted to estimate the effect of region of 
origin, accounting for competing risks and adjusting for any confounders. 
 Time to ART initiation and time to AIDS diagnosis were analysed using a similar 
method, but censoring each patient at the date of the last follow-up visit. In this case, 
only death was recorded as a competing event. Finally, time to all-cause mortality was 
analysed using a standard multivariate Cox regression model. 
In all four survival models, patients who fulfilled the outcome definition at re-
cruitment were excluded from the analysis. Taking into account that all subjects are 
ART naïve at entry, for analysis of time to ART requirement and time to ART initiation, 
patients who started ART on the day of recruitment were artificially given one day of 
follow-up. Analyses were repeated excluding these patients as a sensitivity analysis, 
but no changes were observed. All four models were adjusted by CD4 count and VL at 
recruitment, to account for duration of infection prior to recruitment[78]. Sensitivity 
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analyses excluding patients with missing information in either CD4 count or VL were 
carried out, with no impact on results. 
A pooled logistic regression was performed alternatively for all four outcomes 
in order to adjust for informative censoring trough inverse probability weighting. The 
current cumulative month of follow-up and the cubic splines of the months with five 
knots at percentiles 5, 22.5, 50, 72.5 and 95, were used to account for time and intro-
duced in the model. Patients who had not had any follow-up visit in the year prior to 
administrative censoring were considered to be lost to follow-up. The probability of 
not being LTFU at each month of patient’s follow-up was calculated taking into account 
all socio-demographical variables, CD4 count, VL, and clinical and treatment status at 
baseline and at every particular month. As a sensitivity analysis, LTFU was defined as 
subjects who had not had any follow-up visit two and three years prior to administra-
tive censoring, and results remained unchanged. 
Finally, time to virological and immunological response to treatment was ana-
lysed through a Fine and Gray regression, considering deaths occurred before response 
as a competing event and censoring each patient at their last Viral Load or CD4 count 
assessment, respectively. 
For every outcome, interaction between region of origin and sex was system-
atically explored, to assess if any gender differences were observed. Other interactions 
could not be explored due to insufficient sample size. Proportionality of hazards as-
sumption was tested for region of origin and every outcome. 
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Statistical significance was evaluated using the Wald test. All the analyses were 
conducted using Stata software (V.11.1, Stata Corporation, College Station, Texas, 
USA). 
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6.1. Results for Objective 1 
6.1.1. Characteristics of the sample 
From 1986 to 2009, 479 seroconverters were identified with a median serocon-
version in August 1999 (IQR: December 1992- June 2005). 60% of the sample were 
subjects infected after 1996, in the HAART era. Considering patients with no clinical 
follow-up visit in the last three years as lost to follow up, the percentage of patients 
lost was 35%, and median follow-up time for the total cohort was 3.7 years (IQR:1.2-
9.2). 
In 433 subjects (90.4%) seroconversion was estimated as the mid-point be-
tween a previous negative and the first positive test, and median interval between 
both tests was 0.96 years (IQR: 0.57-1.57). In the remaining 46 subjects (9.6%) sero-
conversion was established on the date of a Western Blot test with an undetermined 
result. In this latter percentage of women was 19.9 points higher (CI: 0.06-0.34; 
p<0.01) and subjects were a mean of 3.0 years younger (CI: 0.70-5.30; p=0.01).  
Out of the sample subjects, 80% were MSM, followed by 14% of IDU. The ma-
jority were males with high educational level (68.9% of the total sample). Median age 
at seroconversion was 29.4 (IQR: 25.1-34.5). Most of the patients were of Spanish ori-
gin (78.9%), although there was a considerable proportion of subjects coming from 
Latin America and the Caribbean (15.4%). Median CD4 count at diagnosis was 
663cells/mm3 (IQR: 501-826). Significant differences were found in the sample accord-
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ing to educational level, so Table 1 shows baseline characteristics of the sample strati-
fied by this variable. 
Table 1. Baseline characteristics of the sample by educational level. 
 Low  education 
N=105 (21.9%) 
High education 
N=330 (68.9%) 
Education unknown 
N=44 (9.2%) 
Total 
N= 479 
P* 
n % n % n % n %  
Transmission category 
Homo/bisexual 56 53.3 291 88.2 36 81.8 383 80.0 0.000 
Heterosexual 8 7.6 18 5.4 1 2.3 27 5.6 
Injecting drug user 40 38.1 20 6.1 7 15.9 67 14.0 
Other 1 1.0 1 0.3 0 0.0 2 0.4 
Sex 
Males 88 83.8 311 94.2 41 93.2 440 91.9 0.003 
Females 17 16.2 19 5.8 3 6.8 39 8.1 
Age at seroconversion 
# in each group 105 329 44 478 0.000 
Median (IQR) 26.3 (22.3-32.8) 30.1 (26.3-34.8) 30.1 (25.8-35.2) 29.4 (25.1-34.5) 
Region of origin 
Spain 90 85.7 253 76.7 35 79.5 378 78.9 0.337 
Europe 4 3.8 11 3.3 3 6.8 18 3.8 
Latin America  10 9.6 59 17.9 5 11.4 74 15.4 
Other 1 0.9 7 2.1 1 2.3 9 1.9 
Seroconversion date 
1986 – 1996 67 63.8 104 31.5 20 45.5 191 39.9 0.000 
1997 – 2009 38 36.2 226 68.5 24 54.5 288 60.1 
Calendar period** 
1986 – 1996 64 39.7 99 23.7 20 31.7 183 28.5 0.001 
1997 – 2009 97 60.3 319 76.3 43 68.2 459 71.5 
CD4 at diagnosis*** 
# in each group 70 264 29 363 0.318 
Median (IQR) 699 (544-885) 649 (488-823.5) 665 (540-756) 663 (501-826) 
VL at diagnosis *** 
# in each group 33 204 21 258 0.602 
Median (IQR) 39603  
(9219-82832) 
32585.5 
(10045-87284.5) 
26192 
(5886-64771) 
32333 
(9885-86172) 
*Statistical significance (p-value) for the difference between the three groups of educational level. Chi2 
used for categorical variables and Kruskal-Wallis test for continuous. Results remain largely unchanged if 
comparison is established only between both groups with known educational level; **Subjects are con-
sidered to belong to a calendar period if he/she contributes any follow-up time to that period, so a pa-
tient can simultaneously contribute to both periods. Therefore, total number of patients for this variable 
is larger than total number of patients in the sample; *** For these variables, CD4 counts and VL are 
considered when performed within a 3-month interval from the first HIV positive test; IQR: Interquartile 
range. 
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Patients with a lower educational level comprised a higher proportion of IDU, 
of women, of native Spanish patients, were younger and corresponded to infections 
acquired in more early stages of the HIV epidemic, with a higher proportion of sero-
conversions in the period before 1996. 39.9% of patients were prescribed antiretrovi-
ral treatment at some point of their follow up, being HAART in an 89% of cases. 
6.1.2. Cumulative incidence of AIDS  
During the total follow-up time of 2,953 person-years (py), 59 cases of AIDS 
were diagnosed, for an incidence rate of 20.0 cases per 1000 py. Incidence rate was 
three times higher before 1997 (38.4/1000py) than after that date (13.3/1000py).  
Figure 1 shows cumulative incidence of AIDS function in each calendar period. 
As for variables associated with risk of AIDS, in the crude analysis only educational 
level and calendar period showed any effect. Results for all evaluated variables can be 
found in Table 2 and Figure 2 shows cumulative incidence of AIDS by each group of 
educational level, being worthy of note that subjects of high educational level showed 
a lower risk of AIDS at all points of patients’ follow up. 
Multivariate modelling selected three independent predictors for risk of AIDS: 
calendar period, educational level and age at seroconversion. The latter could be in-
troduced as a continuous variable in the model.   
Adjusted HR showed that after 1997 risk of AIDS was reduced by a 78.5% 
(95%CI: 48.1-89.0; p<0.01).  Effects of both age and educational level were found to be 
different in each calendar period: p-value of the interaction between period and age 
was 0.006; and p-value for interaction with educational level was not significant 
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(p=0.396), but HR for the two calendar periods differed by 33.4%, so a possible effect 
modification was taken into account.  
Figure 1. Cumulative incidence of AIDS by cal-
endar period 
Figure 2. Cumulative incidence of AIDS by edu-
cational level 
  
Table 2. Risk of AIDS. Results of univariate analysis.  
 HR (CI) p 
Transmission category 
Sexual route and others 1  
Injecting drug user 1.349 (0.788-2.308) 0.275 
Sex 
Males 1  
Females 1.269 (0.666- 2.419) 0.470 
Region of origin 
Spain 1  
Latin America  1.440 (0.632- 3.283) 0.386 
Other 0.524 (0.067- 4.103) 0.538 
Calendar period 
1986 – 1996 1  
1997 – 2009 0.223 (0.122- 0.410) 0.000 
Educational level 
Low 1  
High 0.511 (0.293-0 .891) 0.018 
Unknown 0.874 (0.380- 2.013) 0.752 
Age at seroconversion 1.000 (0.965-1.035) 0.980 
CD4 at diagnosis (n=454) 0.999 (0.998-1.001) 0.541 
CV at diagnosis (n=254) 1.000 (0.999-1.000) 0.905 
HR: Hazard Ratio; CI: Confidence Interval 
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Table 3. Risk of AIDS stratified by period. Results of multivariate analysis.  
 HR (CI) p 
Educational level 
1986 - 1996 Low 1  
High 0.668 (0.314- 1.424) 0.297 
Unknown 0.547 (0.158- 1.897) 0.342 
1997 - 2009 Low 1  
High 0.445 (0.192- 1.031) 0.059 
Unknown 0.986 (0.319- 3.049) 0.980 
Age at seroconversion 
1986 - 1996 Age (in years) 1.071 (1.038- 1.105) 0.000 
1997 - 2009 Age (in years) 0.982 (0.936- 1.031) 0.465 
HR: Hazard Ratio, CI: Confidence Interval 
Table 3 shows the effect of both age and educational level stratified by calen-
dar period. Before 1997, risk of AIDS increased by 7.0% (95%CI: 3.8-10.5) for each year 
of age at seroconversion, and in this period, no effect of educational level over risk of 
AIDS is evident. As opposed to these findings, in the HAART era (after 1997), individu-
als of high educational level came to have 55.5% lower risk of AIDS (95%CI: 80.8% 
lower-3.1% higher), and no effect of age is longer observed. Transmission category was 
not statistically significant in the adjusted analysis. 
6.1.3. Cumulative incidence of all-cause mortality  
During a total follow-up of 3,494 person-years (py) 27 deceases were observed, 
for an incidence rate of 7.7/1000py. Incidence rate was four times higher before 1997 
(16.7/1000py) than after this year (4.9/1000py). Univariate analysis results are shown 
in Table 4. Variables with a crude effect over risk of death were transmission category, 
educational level and calendar period. Figure 3 shows risk of death by calendar period 
and points out a higher incidence of deaths in the period previous to 1997. Figure 4 
shows cumulative risk of death by educational level. 
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Table 4. All-cause mortality risk. Results from univariate analysis.  
 HR (CI) p 
Transmission category 
Sexual route and others 1  
Injecting drug user 2.282 (1.096-4.751) 0.027 
Sex 
Males 1  
Females 1.440 (0.553-3.595) 0.472 
Region of origin 
Spain 1  
Latin America  1.446 (0.438-4.773) 0.545 
Other 1.410 (0.182-10.907) 0.742 
Calendar period 
1986 – 1996 1  
1997 – 2009 0.148 (0.059-0.374) 0.000 
Educational level 
Low 1  
High 0.357 (0.157-0.813) 0.014 
Unknown 0.725 (0.203-2.581) 0.619 
Age at seroconversion 1.018 (0.966- 1.073) 0.499 
CD4 at diagnosis (n=454) 0.998 (.996-1.001) 0.135 
CV at diagnosis (n=254) Cannot be estimated* 
* In the group of patients with available information on VL at HIV diagnosis there was no decease ob-
served, so HR could not be estimated. HR: Hazard Ratio, CI: Confidence Interval 
Figure 3. Cumulative incidence of all-cause mortal-
ity by calendar period 
Figure 4. Cumulative incidence of all-cause mortal-
ity by educational level 
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Results of the adjusted analysis can be found in Table 5. Adjusted effect for cal-
endar period shows survival after HAART availability was improved by 86.6% (95%CI: 
65.4-94.8). People with high educational level had 61.7% (95%CI: 12.5-83.2) less risk of 
dying compared to those with low educational level. Effect of transmission category 
was no longer observed after adjusting for educational level. Risk of death increased 
by 4.8% (95%CI: 1.4-8.4) for each year of age at seroconversion. Both effects were ho-
mogeneous throughout the study period. 
Table 5. All-cause mortality risk. Results from multivariate analysis.  
 HR (CI) p 
Calendar Period 
1986 – 1996 1  
1997 – 2009 0.134 (0.052- 0.346) 0.000 
Educational level 
Low 1  
High 0.383 (0.168- 0.875) 0.023 
Unknown 0.693(0.184- 2.613) 0.588 
Age at seroconversion 1.048 (1.014- 1.084) 0.006 
HR: Hazard Ratio, CI: Confidence Interval 
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6.2. Results for Objective 2 
6.2.1. Characteristics of the sample 
For the period between April 1983 and February 2009, 1772 patients were in-
cluded in the cohort, with a median seroconversion date on December 1994 (IQR): July 
1991 - December 1999. The median seroconversion window (time between the last 
negative and first positive test) was 1.0 years (IQR: 0.6-1.7).  
A total of 783 (44.2%) patients did not have information on educational level 
and were excluded. 67.4% of them corresponded to IDU from a prison cohort and a 
detoxification unit. Compared to those with available information, they were younger, 
with a higher proportion of IDU, women and people with missing region of origin, had 
been recruited in early calendar periods, had been imprisoned in their life-time and 
had lower CD4 counts at entry.  
The final sample for analysis consisted of 989 persons. Of these, 9.7% had not 
completed primary education, 42.4% had only achieved primary education, 28.8% had 
secondary education and 19.1% had completed studies beyond secondary education. 
In all, 515 subjects (52.1%) were included in the category of low education and 474 
(47.9%) in the category of high education. Some 52.4% were IDU, and the rest of the 
sample was composed of MSM (85.1%) and heterosexuals (11.7%), with a small pro-
portion (3.2%) of unknowns.  
Table 6 shows a description of the sample by educational level and calendar pe-
riod. The low education group was composed mostly of IDU, had more women and 
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young people and fewer foreigners than the high education group. In more recent cal-
endar periods, patients had higher education, were older, more likely to be foreigners 
and acquired the infection by sexual transmission. No differences were detected with 
regards to CD4 or viral load at the time of diagnosis by educational level. 
Table 6. Socio-demographic and clinical characteristics by educational level 
 Low education 
N=515 (100%) 
High education 
N=474 (100%) 
Total 
N=989 (100%) 
p 
n % n % n %  
Transmission category  
Sexual route and others 106 20.6 365 77.0 471 47.6 0.000 
Injecting drug users 409 79.4 109 23.0 518 52.4 
Sex  
Males 394 76.5 418 88.2 812 82.1 0.000 
Females 121 23.5 56 11.8 177 17.9 
Age at seroconversion  
Median (IQR) 25.6 (22.7-29.4) 29.8 (25.4-34.5) 27.4 (24.0-32.5) 0.000 
Region of origin  
Spain 467 90.7 373 78.7 840 84.9 0.000 
Europe 8 1.5 14 2.9 22 2.2 
Latin America and the Caribbean 11 2.1 64 13.5 75 7.6 
Other 3 0.6 7 1.5 10 1.0 
Unknown 26 5.1 16 3.4 42 4.3 
Method of estimating serocon-
version 
 
Evidence of seroconversion 10 1.9 32 6.75 42 4.25 0.000 
Mid-point between (-) and (+) 505 98.1 442 93.25 947 95.75 
Calendar period*  
<=1996 362 35.5 169 21.8 531 29.6 0.000 
1997-2003 397 38.9 261 33.6 658 36,7 
>=2004 261 25.6 346 44.6 607 33,8 
CD4 at diagnosis** (cells/µl)  
N in each group 210 338 548 0.993 
Median (IQR) 611 (464-857) 630 (459-817) 623 (462.5-831.5) 
Viral load at diagnosis ** (cop-
ies/µl)  
 
N in each group 77 250 327 0.326 
Median (IQR) 46.6 (9.8-159.0) 35.8 (10.0- 98.2) 36.8 (10.0– 108.2) 
* Each subject is counted if he/she contributes periods of risk to the period, therefore the total for this 
variable is larger than the total number of subjects; ** Taken from tests made on the date of the first 
positive result plus/minus 3 months; IQR: Interquartile range; p: statistical significance, calculated by Chi 
square for categorical variables and Mann-Whitney test for continuous variable. 
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6.3. Results for Objective 3 
6.3.1. Characteristics of the sample 
Of the 6811 subjects recruited in CoRIS up to October 2010, 6278 (92.2%) were 
either native Spanish (NSP, n= 4657, 74.2%), Latin Americans and Caribbeans (LAC, 
n=1221, 19.4%) or Sub-Saharan Africans (SSA, n=400, 6.4%). NSP were older, more 
frequently infected through injecting drug use (IDU) and had higher viral loads, both at 
recruitment and at treatment initiation (Table 8). The majority of LAC were men who 
have sex with men (MSM), had higher educational level and higher percentage of CDC 
stage A at recruitment. SSA had the highest proportion of females, heterosexual 
transmission, lower education, delayed diagnosis, CDC stage C and lowest CD4 counts 
at recruitment. Both LAC and SSA had been enrolled in CoRIS more frequently in recent 
years. Importantly, no differences were found in CD4 counts at ART initiation.  
Figure 8 shows a flow chart specifying which population contributed to the as-
sessment of each of the outcomes and which criteria where applied for subjects exclu-
sion. No differences were found by sex in any of the analysis.   
6.3.2. HIV Diagnostic Delay by region of origin 
Of the 4894 patients assessed, diagnostic delay (DD) of HIV infection was ob-
served in 2434 (49.7%). Prevalence of DD was significantly lower in NSP (48%) com-
pared to both LAC (51.6%) and SSA (62.8%). 
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Table 8. Characteristics of the sample by geographical origin of the patient. 
 NSP LAC SSA Total  
N=4657 N=1221 N=400 N=6278 P* 
Sex                                    [n(%)]                                                                                 
Male 3884 (83.4) 986 (80.7) 183 (45.8) 5053 (80.5) <0.001 
Female 773 (16.6) 235 (19.2) 217 (54.2) 1225 (19.5) 
Age                                                                     
[Median (IQR)] 37 (30-43) 32 (27-38) 31 (27-38.5) 35 (29-42) <0.001 
Mode of transmission        [n(%)]                                                                                                                                     
MSM  2364 (50.8) 770 (63.1) 8 (2.0) 3142 (50.1) <0.001 
Heterosexual 1324 (28.4) 406 (33.2) 358 (89.5) 2088 (33.3) 
IDU 798 (17.1) 17 (1.4) 9 (2.3) 824 (13.1) 
Other/NA 171 (3.7) 28 (2.3) 25 (6.3) 224 (3.6) 
Educational level               [n(%)]                                                                           
Secondary or Higher  2281 (49.0) 664 (54.4) 87 (21.7) 3032 (48.3) <0.001 
Primary or none 1624 (34.9) 386 (31.6) 218 (54.5) 2228 (35.5) 
Unknown 752 (16.1) 171 (14.0) 95 (23.8) 1018 (16.2) 
CDC stage                         [n(%)]                                                                       
A/P 3510 (75.4) 971 (79.5) 280 (70.0) 4761 (75.8) <0.001 
B 425 (9.1) 91 (7.5) 32 (8.0) 548 (8.7) 
C 599 (12.9) 133 (10.9) 81 (20.3) 813 (13.0) 
Unknown 123 (2.6) 26 (2.1) 7 (1.8) 156 (2.5) 
Year of recruitment            [n(%)] 
2004-2006 1872 (40.2) 408 (33.4) 151 (37.8) 2431 (38.7) <0.001 
2007-2010 2785 (59.8) 813 (66.6) 249 (62.3) 3847 (61.3) 
Delayed diagnosis             [n(%)] 
No 1865 (40.1) 472 (38.7) 123 (30.8) 2460 (39.2) <0.001 
Yes 1723 (37.0) 503 (41.2) 208 (52.0) 2434 (38.8) 
Unknown 1069 (23.0) 246 (20.2) 69 (17.3) 1384 (22.1) 
Losses to Follow-up          [n(IR)] 996 (8.1) 309 (11.1) 168 (19.7) 1473 (9.3) <0.001 
CD4 count at 
enrolment 
(cells/mm3)  
n 4440 1160 379 5979 <0.001 
[Median (IQR)] 364 (180-572) 350.5 (171.5-527) 284 (130-474) 357 (175-555) 
Viral Load at 
enrolment   
(log copies/ml)  
n 4420 1152 373 5945 <0.001 
[Median (IQR)] 4.66 (4.05-5.16) 4.56 (3.97-5.07) 4.58 (3.65-5.11) 4.64 (4.01-5.14) 
CD4 count at 
ART 
(cells/mm3)  
n 2167 510 196 2873 0.945 
[Median (IQR)] 210 (85-306) 210 (97-302) 208.5 (92.5-
287.5) 
210 (89-302) 
Viral Load at 
ART   
(log copies/ml)  
n 2129 501 193 2823 <0.001 
[Median (IQR)] 4.99 (4.44-5.40) 4.80 (4.27-5.28) 4.83 (4.06-5.18) 4.94 (4.37-5.37) 
NSP: Native Spanish; LAC: Latin America and the Caribbean; SSA: Sub-Saharan Africa; CDC: Centres for 
Disease Prevention and Control; IQR: Interquartile range; IR: Incidence Rate per 100 persons-year of 
follow up* p-values are for Chi-sq, Kruskal-Wallis or Log-Rank (as appropriate) for differences across 
regions.  
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Transmission route was a confounder of the association between region of ori-
gin and diagnostic delay, and an interaction was found between region of origin and 
age, so adjusted Odds Ratios (ORs) are shown stratified by age (Table 9). SSA below 35 
years of age had a risk of DD which doubled that of young NSP, while older SSA 
showed no difference. For LAC, the excess risk compared to NSP was seen for subjects 
under 50, being more pronounced at ages under 35. 
Figure 8. Flow chart of the sample. Population used to assess each outcome. 
 
(a) Patients assessed for Delayed Diagnosis; (b) Patients assessed for risk of death; (c) Patients assessed 
for time until ART initiation; (d) Patients assessed for risk of AIDS; (e) Patients assessed for time until 
ART requirement; (f) Patients assessed for virological response to ART; (g) Patients assessed for immu-
nological response to ART 
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Table 9. Results of the univariate and multivariate analysis for all the outcomes in the study 
 SSA  OR/HR [95%CI] LAC  OR/HR [95%CI] 
OUTCOME # Events / Na (%; IRb) Crude Adjustedc Crude Adjustedc 
Diagnostic Delay 
Age   
1.83 [1.45-2.31]** 
Age 
1.15 [1.00-1.33]* 
Age  
<35 948 / 2382 (39.8) <35 2.02 [1.47-2.78]** <35 1.69 [1.39-2.06]** 
35-50 1116 / 1987 (56.2) 35-50 1.15 [0.78-1.72] 35-50 1.28 [1.00-1.64]* 
>50 370 / 525 (70.5) >50 0.42 [0.14-1.24] >50 0.84 [0.44-1.62] 
ART requirement  1897 / 4306 (44.1) 1.22 [1.00-1.49]* 0.90 [0.67-1.21] 1.13 [1.01-1.26]* 1.02 [0.88-1.18] 
ART initiation  3521 / 5765 (61.1) 1.43 [1.16-1.62]** 1.06 [0.91-1.24] 1.01 [0.93-1.09] 0.91 [0.84-1.00]* 
Immuno. response  2226 / 2578 (86.3) 0.81 [0.69-0.96]* 0.80 [0.67-0.96]* 1.02 [0.92-1.13] 1.04 [0.94-1.16] 
Viro. response  2064 / 2726 (75.7) 0.79 [0.65-0.94]* 0.74 [0.61-0.90]** 1.01 [0.90-1.13] 1.00 [0.89-1.13] 
AIDS 
Age   
1.17 [0.77-1.78] 
Age 
0.80 [0.60-1.06] 
Age  
<35 109 / 6422 (1.7) <35 0.94 [0.46-1.91] <35 0.71 [0.44-1.14] 
35-50 201 / 5334 (3.8) 35-50 2.05 [1.12-3.74]* 35-50 1.58 [1.05-2.40]* 
>50 64 / 1140 (5.6) >50 1.47 [0.27-7.87] >50 0.25 [0.04-1.79] 
AIDS (excl. TB)  250 / 12897 (1.9) 1.04 [0.60-1.80] 1.26 [0.70-2.26] 0.85 [0.61-1.19] 1.19 [0.81-1.74] 
Death  231 / 15868 (1.5) 0.62 [0.32-1.21] 0.66 [0.31-1.39] 0.54 [0.35-
0.81]** 
0.85 [0.55-1.30] 
SSA: Sub-Saharan Africa; LAC: Latin America and the Caribbean; OR: Odds Ratio; HR: Hazard Ratio; IR: Incidence Rate per 100 person-years; a Denominator differs between 
outcomes: Diagnostic Delay (DD): number of subjects assessed for DD in each age group; The rest of outcomes: person-years at risk; b Percentage is shown for DD outcome. 
IR is shown for the other 7 outcomes; c For DD outcome, OR is shown adjusted by transmission route and age at recruitment; For time to ART requirement HR was adjusted 
by CD4 count and viral load (VL) at recruitment; For time to ART initiation, HR was adjusted by CD4 count and VL at recruitment and transmission route; For time to immu-
nologic response and time to virological response, HR was adjusted by CD4 count and VL at treatment initiation; For time to AIDS, time to AIDS excluding TB and time to 
death, HR was adjusted for CD4 count and VL at recruitment, transmission route and age at recruitment; * p<0.05; ** p<0.01. 
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6.3.3. Access to treatment by region of origin 
Of the 3889 subjects assessed for ART requirement (4306 person-years of fol-
low-up), 1897 subjects required treatment (48.8%; Incidence rate 44.1/100py), higher 
for SSA (68.1/100py) and LAC (49.5/100py) compared to NSP (41.6/100py). Figure 9 
shows the cumulative incidence of ART requirement by geographical origin of the pa-
tient. Crude Hazard Ratios (HRs) showed this faster progression to ART requirement for 
both groups, which disappeared after adjusting for CD4 counts and VL at recruitment 
(Table 9), suggesting the effect of recruitment in later stages of disease and therefore, 
shorter time to ART requirement at the crude level, but not after adjusting for duration 
of infection.  
Figure 9. Cumulative incidence of ART requirement and ART initiation by 
region of origin 
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faster ART initiation for SSA, which disappears after adjusting for CD4 count and VL at 
recruitment and transmission route. LAC do not show any difference in the crude 
analysis, but a higher risk of a delayed initiation of ART of small magnitude and clinical 
relevance is observed after adjustment (Table 9). Initial antiretroviral regimes for NSP, 
LAC and SSA are shown in Table 10, and no differences are observed. 
Table 10. Initial Antiretroviral Therapy regime by region of origin 
NSP: Natural Spanish; SSA: Sub-Saharan Africa; LAC: Latin America and The Caribbean; NRTI: nucleotide 
reverse transcriptase inhibitors; NNRTI: non-nucleotide reverse transcriptase inhibitors; PI: protease 
inhibitors. Fisher’s exact p-value for the table=0.36. 
6.3.4. Response to treatment by region of origin 
Of the 2724 subjects assessed for immunological response, 2226 (81.7%) re-
sponded at some point in time, 1896 (69.6%) within the first year of ART. Global re-
sponse rate was 86.3/100 py, and was lower for SSA (71.8/100py) compared to NSP 
(86.9/100py) and LAC (89.4/100py).   
2641 patients were assessed for virological response, of which 2064 responded 
at some time (78.2%) and 1852 (70.1%) within the first year. Virological response rate 
ART initial regime [n(%)] NSP SSA LAC Total 
2 NRTI + 1 NNRTI 1448 (56.6) 134 (55.1) 376 (58.0) 1998 (56.8) 
2 NRTI + 1 PI/r 877 (33.4) 85 (35.0) 202 (31.2) 1164 (33.1) 
2 NRTI + 1PI 55 (2.1) 7 (2.9) 16 (2.5) 78 (2.2) 
2 NRTI+ 1 Integrase Inhibitor 37 (1.4) 1 (0.4) 16 (2.5) 54 (1.5) 
3 NRTI 42 (1.6) 3 (1.2) 7 (1.1) 52 (1.5) 
Other 131 (4.9) 13 (5.3) 31 (4.8) 175 (5) 
TOTAL 2630 (100) 243 (100) 648 (100) 3521 (100) 
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was 75.7/100py globally and again was significantly lower for SSA (61.5/100py) com-
pared to NSP (76.5/100py) and LAC (77.6/100py).  
Figure 10 shows cumulative incidence of immunological and virological re-
sponse by region of origin. Higher risk of delayed immunological and virological re-
sponse in SSA was observed in the crude analyses and after adjustment for CD4 count 
and VL at ART initiation, while no differences were found for LAC (Table 9). 
Figure 10. Cumulative Incidence of immunological and virological response 
by region of origin 
  
 
Total number of CD4 count determinations after treatment initiation was 8 
(IQR:4-12), slightly higher for NSP (8; IQR:5-13) than for LAC (7; IQR:4-12) and for SSA 
(6; IQR:3-10) , with a p-value for differences across three groups <0.01. Number of VL 
determinations showed similar significant differences across regions (p<0.01), being 
for 8 determinations for NSP (IQR:5-13), 7 for LAC (IQR:4-11) and 6 for SSA (IQR:4-10). 
However, none of these variables showed any confounding effect between region of 
origin and immunological or virological response. 
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6.3.5. Risk of AIDS and death by region of origin 
Of the 5242 patients evaluated -12898 py of follow up-, 374 were diagnosed of 
AIDS during their follow-up (7.1%, IR 2.9/100py), 280 of them within the first year. 
AIDS defining illnesses (ADIs) by region of origin are described in Figure 11. AIDS inci-
dence was highest for SSA (3.7/100py), lowest for LAC (2.4/100py) and intermediate 
for NSP (3.0/100py). Figure 12 shows the cumulative incidence of AIDS by region of 
origin, and cumulative incidence when tuberculosis as an AIDS defining illness is ex-
cluded from the analysis. 
Figure 11. Initial AIDS defining illnesses of incident AIDS diagnosis (n=374) 
by region of origin  
 
Pn. Jirovecii: Pneumocystis jirovecii pneumonia; TB: Mycobacterium tuberculosis; pulm.: pulmonary; 
diss: disseminated; extrapulm.: extrapulmonary; PMLE: Progressive multifocal leukoencephalopathy; 
ADIs: AIDS defining illnesses. *One patient can simultaneously experience more than one ADI at AIDS 
diagnosis, so total “n” is larger than total number of patients.   
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Crude HR showed no significant differences across regions. Age was found to 
modify the effect of the region of origin, so HRs are shown stratified by age and ad-
justed for CD4 count and VL at recruitment and transmission route (Table 9). Adjust-
ment revealed a higher risk of AIDS for both SSA and LAC in the medium ages (35 to 50 
years old). A sub-analysis was performed excluding Tuberculosis (TB) and no differ-
ences in risk of AIDS were longer observed. Among the 5991 subjects -15868 py-, that 
were included for the overall survival analysis, 231 patients died (3.9%, IR 1.5/100py). 
Death rate was higher for NSP (1.6/100py), followed by LAC (1.1/100py) and lowest for 
SSA (0.9/100py). 
Figure 12. Cumulative incidence of AIDS by region of origin, with and without 
including tuberculosis as an AIDS defining illness 
  
 
Figure 13 shows cumulative incidence by geographical origin. Crude analysis 
showed longer survival for LAC and SSA, reaching statistical significance for LAC. After 
adjusting for CD4 count, VL, transmission route and age, a non-significant lower risk of 
death was still observed, especially for SSA. 
 
0,
00
0,
05
0,
10
0,
15
0 1 2 3 4 5 6
Years of follow-up
NSP SSA
LAC
Cumulative Incidence of AIDS (total)
0,
00
0,
05
0,
10
0,
15
0 1 2 3 4 5 6
Years of follow-up
NSP SSA
LAC
Cumulative Incidence of AIDS (excl.TB)
6. Results                         Susana Monge Corella 
86 
Figure 13. Cumulative incidence of death by region of origin 
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7. DISCUSSION 
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7.1. Discussion of results 
Our study provides important evidence on the role of socioeconomic variables, 
specifically educational level and migration background on the progression of HIV in-
fection. These results are important to inform appropriate preventive and health care 
services to respond to specific challenges posed by these groups, both at the clinical 
care level and from the perspective of health programmes and policies. 
Regarding the First study Objective, “To identify socioeconomic and demo-
graphic variables influencing prognosis since HIV seroconversion in Madrid (Spain), 
before and after the generalisation of HAART”, risk of HIV disease progression to the 
endpoints of AIDS and death has shown to have decreased greatly after 1997, by 
78.5% and 86.6% respectively. This data confirm HAART effectiveness in the population 
recruited and followed up in the Centro Sanitario Sandoval that receives treatment in 
different hospitals of the Autonomous Community of Madrid. Educational level and 
age at seroconversion have demonstrated to have an independent effect over disease 
progression, but their effect has been found to be different before and after the gen-
eralisation of HAART. This means that age and educational level determine groups 
where benefits of available resources are being unevenly experienced. These results 
are consistent with previous findings in this same cohort in the year 1999[40], al-
though the longer follow-up has allowed us to better characterise the different effects. 
Age at seroconversion determines a higher risk of both AIDS and death in years 
prior to generalisation of HAART. However, the effect over progression to AIDS disap-
pears after 1997, pointing out a higher effectiveness of HAART at higher ages. This re-
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sults are consistent with findings from other authors[88, 105], but are contrary to what 
one would expect based on studies that reveal that younger subjects have a better 
immune reconstitution after treatment, as this effect should have widened the age 
gap[106-108]. Possible explanations are a better acceptance and adherence to treat-
ment in older subjects, a better virological suppression[107, 109], or simply a higher 
margin for AIDS-free survival improvement in older subjects.  
The effect of age on overall survival was constant over the different periods, 
which is also compatible with previous studies[109].Possible explanations for this con-
stantly higher mortality risk are more severe opportunistic diseases in older ages, more 
frequent co-morbidities or higher non-AIDS mortality. This last hypothesis could not be 
contrasted in our study, as the cross-match with the National mortality registry from 
the National Institute of Statistics could only retrieve death episodes, but causes of 
death were not provided. Importance of non-AIDS events is increasing due to the 
higher life expectancy of HIV infected patients, and to the higher proportion of sub-
jects infected in older ages. Non-AIDS-defining events should constitute a priority area 
for research to better manage an increasingly aged HIV epidemic. 
HIV transmission route was associated with cumulative incidence of death at a 
crude level, and being infected through IDU was a risk factor for higher mortality. 
However, this effect is no longer observed after adjustment by educational level. In 
fact, in our sample, the majority of IDUs present low educational level, whereas the 
majority of sexual infections occur within people of high education. Several previous 
works have explored the effect of exposure category over risk of AIDS, but results are 
very heterogeneous[88, 106, 110, 111]. In cases where MSMs outstand with a higher 
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risk of progression to AIDS, it has been attributed to a higher incidence of Kaposi’s sar-
coma, which usually appears at higher CD4 counts than other opportunistic infections. 
On the other hand, those studies that found IDU were the ones with an excess of risk 
of AIDS, explanations have included a worse access and adherence to treatment and a 
higher prevalence of co-infections. More studies are needed to characterise the effect 
of the transmission route of HIV in our context before and after the generalisation of 
HAART, and to clarify its relationship with educational level. 
People of high educational level had a 56% lower risk of AIDS in the HAART era, 
although not before that time. A 62% less risk of death was also found, with no differ-
ences over periods. These results were further corroborated by the analysis performed 
to respond to the Second study Objective “To estimate the effect of educational level 
over HIV-disease progression since HIV seroconversion and access to treatment at 
different periods of the HIV epidemic in Spain”, and will be discussed together. In the 
second analysis, we found educational level was a determinant of progression to AIDS 
and death, but not to HAART requirement or initiation.  
In the early stages of the epidemic, in the absence of effective therapeutic re-
sources, no differences by educational level were seen in progression to AIDS, so lower 
education does not confer any disadvantage in the prognosis of HIV infection. How-
ever, after 1996 as effective treatments became available, those with lower education 
benefited to a smaller extent and higher educational level became a protective factor 
for AIDS. As we split the HAART era in two sub-periods for this analysis, we were also 
able to detect a gradient: the more efficacious the available treatments, the higher the 
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magnitude of the AIDS risk gap. Between 1997 and 2003, people of high educational 
level experienced 42% less risk of AIDS, while it reached 74% after 2004.  
These results corroborate what has been previously found in Spain[40], but dif-
fer from what has been reported in other countries, although no study has used data 
after 1999 or has been performed in seroconverters. Schechter et al.[38] observed 
different progression to AIDS by socioeconomic level before HAART times, whereas 
Junghans et al.[41] did not find these differences in the years after HAART. The effect 
of educational level may vary from one country to another, and thus explain the dif-
ferent results. 
In the case of progression to death, our study supports the hypothesis that HIV-
infected persons with higher education have a reduced risk of death. In this analysis 
we found a 32% lower risk of dying for persons of high educational level, a smaller ef-
fect than the one found in the first analysis. Several studies in Spain have shown a 
greater risk of death in the general population associated with a low educational level, 
and have attributed the differences in the younger groups to infectious diseases and, 
specifically, HIV/AIDS[32, 112]. Jarrín et al.[34] found a protective effect of educational 
level on mortality from all causes in IDU after HAART availability, and several studies in 
Spain [33, 35, 39] and a study in British Columbia (Canada)[113], where access to 
HAART is also free and universal, also found that HIV-infected persons with a lower 
socioeconomic level experienced a higher mortality. 
The effect of educational level on mortality was the same in all three calendar 
periods in our study, independent of the availability of HAART, which suggests the exis-
tence of other determinants of inequality besides HIV infection. Many causes of death, 
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like overdose or external causes are not affected by HAART; in fact, 23% of the deaths 
in our study were due to these causes. Attributing a death to HIV is complex, and a 
high degree of misclassification must be assumed, especially with regard to causes 
categorised as infectious diseases or tumours. Partly because of this limitation, and 
partly due to the small sample size, we did not specifically analyse the risk of death 
attributable to HIV. 
Time to HAART initiation showed no difference by educational level, as no dif-
ference was found in time to HAART requirement, suggesting the lack of inequalities in 
access to treatment. This is to be expected in a health system with free, universal cov-
erage, as is the case in Spain. Other studies however, some of them in similar contexts, 
have found differences in access according to socioeconomic level[41]. It is possible 
that in our cohort we did not capture the most marginalised individuals who may not 
have had access to the health system. Thus, the lack of differences in our study popu-
lation does not rule out the possibility that such differences may exist in population 
subgroups that were not represented in our seroconverter sample. 
As no marked differences in access to HAART were observed, the different pro-
gression to AIDS and death in our study could not, in principle, be attributed to that 
factor. But it may be that the effectiveness of HAART depends on educational level, 
because of either poor adherence or worse response to treatment.  
Adherence to treatment is one of the key factors conditioning efficacy and has 
been a challenge since the beginning of the antiretroviral treatments, implying a heavy 
pill burden, coping with frequent adverse events and regular clinical follow-up visits. 
Adherence highly depends on psychosocial factors including emotional stress, quality 
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of the social support network, ability to understand and accept the disease and the 
medical recommendations, different attitudes and use of healthcare resources, and 
alcohol and drug abuse, as well as on clinical aspects like the frequency and severity of 
adverse events and drug toxicity[114-122]. The ability to cope with treatment side ef-
fects can be further influenced by the need to keep them hidden from the social envi-
ronment and thus, the degree of disclosure of the HIV status and with the degree of 
understanding of the treatment and the symptoms. 
However, association between educational level and adherence to ART has not 
been authoritatively established. A recent systematic review found that around one-
third of studies on this subject had found a statistically significant association between 
educational level and adherence, while the rest had not[116]. On the other hand, 
some studies that have directly evaluated the virological, clinical and immunological 
responses to HAART have found lower effectiveness in persons with less education[39, 
123], even after adjusting for adherence to treatment[124]; therefore, other factors 
may be implicated.  
Some hypotheses of why low educational level could increase risk of AIDS and 
death through pathways not related to HAART access and adherence could be differ-
ent lifestyles and nutritional habits[38], different attitudes towards prophylaxis, or 
other social and psychological resources needed to confront stressful life situations 
successfully. A higher co-morbidity in the low education group could also play a role, 
although adjusting for hepatitis C virus and hepatitis B virus co-infection in the subset 
of patients with this information did not modify the results. 
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Regarding results from the Third study Objective “To analyse key HIV-related 
outcomes for migrants originating from Latin America and Sub-Saharan Africa living 
in Spain compared to the native population”, we have found that HIV-positive mi-
grants from Latin America and the Caribbean and from Sub-Saharan Africa show dif-
ferences in the clinical presentation and the prognosis of HIV infection compared to 
native Spanish patients. 
To our knowledge, this is the largest study carried out in HIV-positive migrants 
from Latin America in a European country. Cultural distance, legal status and language 
barriers affect LAC and SSA communities living in Spain differently, and can determine 
different vulnerability, even in the context of a universal health care system. Together 
with their different epidemiological and behavioural backgrounds, this shapes very 
different HIV profiles, as shown in our study and previously[12, 125] which calls for 
studying these groups independently to better identify their needs.  
A higher risk of delayed diagnosis (DD) of HIV infection has been found in mi-
grants in our study, as was previously reported by other authors [61, 62]. What our 
study adds to previous work is the identification of this delayed diagnosis in migrants 
from LAC under 50 years of age, compared to NSP. This can respond to initial legal, 
administrative or cultural barriers to access the system. The similar prevalence of DD 
over 50 years of age between migrants and native Spaniards could reflect, rather than 
an improved situation of the former, a much more frequent DD in the latter[63]. SSA 
also experience a higher frequency of DD below 35 years old, but not after that age. It 
is possible that their ethnic visibility leads physicians to comply with HIV testing rec-
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ommendations when subjects contact the health system, thus protecting them from 
DD.  
As a consequence of the higher frequency of delayed diagnosis in both migrant 
groups, time to requiring ART was shorter and a more prompt ART initiation was found 
in the crude analysis. However, these differences could not be attributed to the region 
of origin but to a more advanced stage of HIV disease at diagnosis. A delayed ART ini-
tiation was still found for LAC after adjustment, although its magnitude was small as 
well as probably its clinical relevance. These results are consistent with existing litera-
ture from European settings[70, 126].  
Immunological and virological responses were poorer for SSA, but not for LAC. 
This difference could not be attributable to different initial ART regimes, which were 
independent of the geographical origin of the patients, as it was probably not attribut-
able to a differential frequency of CD4 counts and VL measurements within the three 
groups compared. Some biological factors have been associated in the literature with a 
worse response to treatment, and thus could partially explain our results, such as spe-
cific viral subtypes and/or resistance mutation profiles[127-131]. There could also be a 
role for differences in laboratory reference parameters[132, 133] or in drug metabo-
lism[134]. However, important factors from the socioeconomic arena are probably 
present [69, 75, 135], especially those related to ART adherence[136].  
An increased rate of treatment adverse events has been described in SSA and 
could affect adherence[137]. Additionally, high geographical mobility, communication, 
language and administrative barriers, stigma and discrimination, different health be-
liefs and habits, low literacy, lack of social support and depression are circumstances 
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that affect SSA communities living in Spain and are negatively associated to adher-
ence[138].  
Consistently with our results, some studies have found more frequent virologi-
cal and immunological failure in the long term in migrants, mainly from SSA[69, 76]. 
Further, previous studies found no difference in immunological and virological re-
sponse in SSA when using a threshold of 400-500 copies/ml, but poorer response when 
considering a target VL of 50 copies/ml[67, 69, 71, 73, 139]. Achieving VL as low as 20 
copies/ml has a demonstrated an impact on sustained virological response, so studies 
should consider target VL as low as possible to be able to capture clinically meaningful 
inequalities[140].  
A higher risk of AIDS in ages between 35 and 50 was found for SSA and LAC, 
which was at the expense of a higher rate of tuberculosis. TB is a known socio-
economically sensitive disease, as it is concentrated in groups with poor living condi-
tions[141, 142]. Further, migrants from SSA and LAC come from countries with higher 
TB endemicity than Spain, which poses them at a higher risk of TB latent infection and 
subsequent reactivation[143].  
As opposed to our findings, published studies have found similar or slightly bet-
ter HIV progression rates to AIDS in SSA[66, 68, 72]. A recently published study by Jar-
rín et al.[70] did not find any difference in the risk of progression to AIDS according to 
geographical origin in a large seroconverter cohort. Although this design is the most 
adequate to study the natural history of disease, it is not fully representative of the 
HIV epidemic, especially regarding migrants, as they include preferably migrants who 
were infected in Europe, who have a good access to the health care system and who, 
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by definition, have not had diagnostic delay. A previous work from Staehelin et al.[74] 
in a seroprevalent cohort also concluded that no differences had been found in HIV 
progression in SSA compared to North-western Europeans, but however showed a 
non-statistically significant 55% increased risk of AIDS, which was attenuated when 
excluding TB as first ADI, which could be explained by a lack of statistical power and 
which would be consistent with our results. 
Finally, a lower mortality was observed in migrants from LAC and SSA compared 
to NSP but it did not reach statistical significance, probably due to a lack of statistical 
power. Other studies have also reported a similar or lower mortality in HIV-infected 
migrants compared to native population[66, 68, 70, 74]. Lower mortality in migrants 
suggests a healthy migrant pattern, responding to a self- selection of healthier subjects 
into migration as reported by other authors[94, 95]. 
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7.2. Methodological discussion 
The results of this Doctoral Thesis need to be interpreted in light of its meth-
odological limitations that could affect its internal and external validity. 
7.2.1. Internal Validity 
The main biases that can affect internal validity of results in the study of the 
natural history and disease progression of HIV infection, are those derived from the 
following circumstances: lack of observation of the event that determines the risk ori-
gin, lack of observation of the event of interest, miss-classification in the independent 
variables, lack of information on variables that could be potential confounders or that 
are important for the discussion of results, possible ecological fallacy in the evaluation 
of the population effectiveness of therapies, and/or low precision of the estimations. 
The possible bias caused by the non-observation of the risk origin was managed 
by left truncation techniques in the case of seroconverter cohorts analysis (objectives 1 
and 2), and by adjustment by CD4 count and VL at recruitment when analysing data 
from a seroprevalent cohort (objective 3). 
Potential biases caused by the absence of observation of the event of interest 
may also have been present. In Objectives 1 and 2, we have analysed data that mostly 
come from ambulatory health centres where HIV infected subjects are followed up 
until they develop any type of complication that requires specialised care or they need 
to start antiretroviral therapy, when they are transferred to hospital HIV units. This can 
prevent the cohort from detecting AIDS-defining events and deaths, as they usually 
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occur in the hospital setting, and thus are more difficult to detect in the ambulatory 
health centres that participate in the cohort. Follow-up of patients in the referral hos-
pitals minimises this problem, and cross-matches with registries were also performed 
to further avoid this information bias.  
However, the assumption that mortality and AIDS registries are complete and 
that persons who do not appear in them are event-free, may lead to an underestima-
tion of the incidence rate. However, there is no reason to think this would differ by 
educational level, so we don’t think that this may have biased our results. There is also 
no reason to think that differences in dates of cross-matches with registries and other 
differences in outcome ascertainment between different cohorts within GEMES will 
depend on individual educational level, so no information bias is likely to have been 
induced for this reason. 
In the case of the analysis of the CoRIS cohort, this problem was not present, as 
it is a hospital-based cohort. However, an informative censoring was found, as charac-
teristics of patients lost to follow-up were different from those who continued in the 
cohort. This means that the non-observation of the event of interest could have a dif-
ferent probability according to patients’ characteristics and affect internal validity of 
results. Specifically, subjects of non-Spanish origin were more frequently LTFU com-
pared to native Spanish. It is, however, unlikely that a salmon bias is present in our 
study, as migrants LTFU were those with better clinical characteristics. Inverse prob-
ability weighting for censoring was performed to minimize this source of bias, although 
results were largely unchanged under this approach, showing that the bias, if any, 
would be of small magnitude. 
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In the third place, a misclassification of independent variables could also have 
affected out study results. As for educational level, it was recorded at time of recruit-
ment, which could lead to a classification bias, since some subjects may have com-
pleted higher-level studies during follow-up. However, the change in category would 
occur in subjects who completed secondary education after recruitment, which is un-
common in an adult cohort. Moreover, this bias would work in favour of the null hy-
pothesis; therefore, it is unlikely to explain our results.  
Selection bias could have also been introduced by the exclusion of those sub-
jects with no information on educational level. Most were young patients infected in 
the early epidemic through IDU, probably of Spanish origin, who had been imprisoned 
in their life-time and had lower CD4 count at diagnosis; a high proportion of them 
probably correspond to people with a low educational level. Because of the poorer 
prognostic factors, we can assume the direction of this selection bias, if it existed at all, 
would also be towards the null. However, no differences were found in time to AIDS or 
death between people with or without information on educational level. 
On the other hand, the way of recording migrant status can also be discussed, 
as it collects a self-referred region of origin, but does not capture other important di-
mensions such as differences within countries of the regions, different ethnical back-
grounds, time since arrival in Spain, country of birth, nationality, legal status, etc. that 
determine different migration profiles with different socioeconomic vulnerability. 
Another limitation stems from having combined MSM and cases of heterosex-
ual transmission into a single category for the first and second analysis, as they have 
different demographic and socioeconomic characteristics. In Spain, some of the het-
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erosexual cases are partners of IDU, with whom they share other determinants, among 
them, a lower educational level than MSM.  
Another aspect that needs to be discussed is that important variables can be 
missing in our study. We have considered educational level as a proxy for social class, 
although it is very possible that this variable alone is not capturing important condi-
tions associated to material and social deprivation with important consequences over 
HIV vulnerability. Educational level is best in measuring psychological and behavioural 
aspects of social class, and is a solid link between life conditions in early youth and 
adulthood. However, variables such as employment status or income, to mention 
some examples, can complement information provided by educational level and refine 
measurement of socioeconomic level in observational studies.  
This situation is probably more evident in migrants, who are often faced with 
loss of social status in the host country, higher unemployment, legal precariousness 
that can result in their living conditions not matching with natives from the same edu-
cational level. So, in this particular group, educational level may be not the best proxy 
to adjust for socioeconomic conditions. Moreover, migrants from different origins may 
have undergone formal education in their countries of origin, which probably have 
different education curricula than Spain, and educational level categories may not be 
fully comparable. However, in every cohort educational level was registered by the 
physician or researcher, choosing the best equivalent in the Spanish educational cur-
riculum for each case, so we expect this misclassification bias is not of significant mag-
nitude. 
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Other unmeasured variables for the third objective were those related to bio-
logical factors, such as viral subtype or prevalence of resistance mutations, as were not 
explored adherence and other specific behavioural aspects with an impact on progno-
sis. 
Another important consideration regarding internal validity of results lies in the 
fact that measuring effectiveness at the population level can be affected by an ecologi-
cal fallacy. The reduced risk in AIDS and mortality observed after 1997 could, there-
fore, not be attributable, or at least not only, to the availability of HAART, but to other 
circumstances like an improvement in general life conditions or other health interven-
tions. In addition, the socio-demographic profile of HIV patients has changed through-
out the calendar periods, so we cannot rule out the possibility that changes in the pro-
file of patients over time partially explain our results. 
Finally, our study may be suffering from lack of statistical power to detect exist-
ing effects. The small proportion of heterosexually infected patients and women 
among the seroconverter subjects is especially notable. In the first case, this forced us 
into grouping sexual transmission categories and prevented us from studying differ-
ences within them, as previously mentioned. In the second case, it is possible that dif-
ferences according to sex were not found even if present, due to insufficient power.  
For the third objective, small sample sizes from regions of origin different to 
Latin America and Sub-Saharan Africa made including these subjects in the analysis 
impossible. The number of SSA could also have been insufficient to detect existing as-
sociations and, in fact, could explain the lack of statistical significance of some effects 
of considerable magnitude. We also did not observe any interaction between sex and 
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region of origin, but we cannot rule out the possibility that this is due to insufficient 
power. 
7.2.2. External Validity 
One of the main challenges of studies addressing the natural history and pro-
gression of HIV infection is recruiting samples who are representative of the general 
HIV-infected population. This one is not a delimited population where the sample 
frame is available, so probabilistic sample selection cannot be used. On the contrary, 
HIV remains to be a stigmatised disease and consequently affected populations are 
relatively hard to reach and recruiting subjects for research studies is a challenge. And 
this may be specially so in the case of migrants, who are a further discriminated popu-
lation, highly mobile and heterogeneous and with a proportion of them facing legal 
barriers to stay in the country. For all the mentioned reasons, recruitment of HIV co-
horts is usually done on a convenience sampling basis and in a health care setting, 
where these populations may be accessible. This can produce a certain degree of se-
lection bias that can limit ability to generalise results to the general HIV-infected popu-
lation.  
In the first place, the Centro Sanitario Sandoval receives a large proportion of 
MSM, who are also the most likely to perform repeated HIV tests. Therefore, MSM are 
over-represented in this sample, as it is in GEMES cohort, at the expense of IDU and 
especially of heterosexually transmitted cases. This, together with the already men-
tioned seroconverter bias, can make the composition of the sample for the first two 
objectives non-representative of the real epidemic.  
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Also, the fact that recruitment is performed in the health care setting, selects 
with a higher probability patients with low barriers to access health care. And this is 
especially true for seroconverters, who are patients that access the system repeatedly. 
We cannot rule out the possibility that our results cannot be generalised to groups of 
patients who may be experiencing higher barriers to access health care. 
Seroprevalent cohorts are more balanced in their composition and have a bet-
ter external validity. However, a certain selection bias can be present, as inclusion in 
cohorts is never randomly assigned. Characteristics of CoRIS patients have been shown 
to be fairly similar to those reported by national surveillance systems, which suggests 
that external validity of data generated in CoRIS will probably be high. 
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Conclusion 1: Availability of HAART after 1996 has shown great population effective-
ness in reducing AIDS incidence and mortality in HIV infected patients in the Spanish 
context. However, progression of infection is further affected by demographic and 
socioeconomic factors, specifically age, educational level and migration status, point-
ing out the existence of social inequalities with an impact on HIV prognosis. 
Conclusion 2: In the absence of effective therapeutic resources, education does not 
determine prognosis of HIV-infected persons; but as effective treatments become 
available, those with lower education benefit to a smaller extent, which reflects in a 
higher risk of AIDS after 1996; and this inequality gap is further widened as treatments 
become more effective. 
Conclusion 3: Higher all-cause mortality in subjects of low educational level is evident 
in the different calendar periods and is not affected by the availability of HAART. This 
points out an overall health vulnerability associated with lower social class which de-
pends on factors beyond HIV infection. 
Conclusion 4: No difference was found on access to HAART by educational level, so this 
factor probably does not explain the higher risk of AIDS and death in subjects of low 
socioeconomic condition. Other factors limiting treatment effectiveness in this group 
may be present probably including, but not limited to, a worse adherence to treat-
ment. 
Conclusion 5: Migrants from Latin America and Sub-Saharan Africa experience a higher 
risk of delayed diagnosis of HIV infection, specially the younger subjects, probably re-
flecting the existence of barriers to HIV testing for these communities. However no 
meaningful delays in treatment initiation are identified, showing an equitable access to 
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therapeutic resources and no further barriers for migrants once they have accessed 
the system.  
Conclusion 6: Immunological and virological response to antiretroviral treatment is 
poorer for Sub-Saharan Africans, but not for Latin Americans. Possible explanatory 
variables were not measured in this study although they probably include a combina-
tion of biological and socioeconomic conditions, including adherence-related factors.  
Conclusion 7: Migrants from Latin America and Sub-Saharan Africa between 35-50 
years old progress faster to an AIDS diagnosis, and it is at the expense of a higher inci-
dence rate of tuberculosis, which is also a socioeconomically sensitive disease. To the 
contrary, mortality in these groups tends to be lower, compatible with the healthy mi-
grant effect. 
Conclusion 8: These results show the impact of social inequalities on HIV-related out-
comes and are important to inform appropriate preventive and health care services as 
well as health programmes and policies to better respond to challenges posed by so-
cial inequalities and to reduce their impact on health. 
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